Heterocyclic PAD4 inhibitors

Heterocyclic compounds are developed to inhibit PAD4 enzyme activity, addressing PAD4-mediated diseases by reducing inflammation and regulating gene expression, offering therapeutic benefits in conditions like rheumatoid arthritis and cancer.

KR103045622B1Active Publication Date: 2026-11-06BRISTOL MYERS SQUIBB CO
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
KR1020227031398
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-02-12
Filing Date
2021-02-11
Publication Date
2026-11-06
Estimated Expiration
2041-02-11

AI Technical Summary

Technical Problem

There is an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated diseases or disorders, including rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, cancer, and other conditions associated with neutrophil extracellular trap formation and epigenetic regulation.

Method used

Development of heterocyclic compounds that inhibit PAD4 enzyme activity, which are administered to subjects to treat diseases or disorders associated with PAD4 enzyme activity, including rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, and cancer, by targeting the citrullination process and epigenetic regulation.

Benefits of technology

The heterocyclic compounds effectively inhibit PAD4 enzyme activity, providing therapeutic benefits in treating PAD4-mediated diseases by reducing inflammation, preventing neutrophil extracellular trap formation, and influencing gene expression, thereby alleviating symptoms and preventing disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112022094909470-PCT00983_ABST
    Figure 112022094909470-PCT00983_ABST
Patent Text Reader

Abstract

The present disclosure relates to a substituted heterocyclic compound of formula (Ia) that is generally an inhibitor of PAD4, a method for preparing the compound, a pharmaceutical composition comprising the compound, and the use of the compound in the treatment of a disease or disorder associated with PAD4 enzyme activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Cross-reference of related applications

[0002] This application claims the benefit of Indian provisional application No. 202041006146 filed on February 12, 2020, the contents of which are specifically incorporated herein by reference.

[0003] Field of invention

[0004] The present invention relates to generally substituted heterocyclic compounds, methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and the use of these compounds in the treatment of diseases or disorders associated with PAD4 enzyme activity. Background Technology

[0005] PAD4 is a member of the peptidylarginine daminases (PAD) family of enzymes capable of catalyzing the citrullination of arginine to citrulline within peptide sequences. PAD4 is responsible for the deiminization or citrullination of various proteins in vitro and in vivo, leading to diverse functional response outcomes in various diseases (Jones JE et al., Curr. Opin. Drug Discov. Devel., 12(5), (2009), 616-627). Exemplary diseases or disorders include rheumatoid arthritis, diseases with a neutrophilic contribution to their pathogenesis (e.g., vasculitis, systemic lupus erythematosus, ulcerative colitis), and oncological indications. PAD4 inhibitors also possess broader applicability as tools and therapeutic agents for human diseases and disorders through epigenetic mechanisms.

[0006] PAD4 inhibitors have utility for rheumatoid arthritis (RA). RA is an autoimmune disease affecting approximately 1% of the population (Wegner N. et al., Immunol. Rev., 233(1) (2010), 34-54). It is characterized by inflammation of the joints that leads to the debilitating destruction of bone and cartilage. Although inconsistent, numerous population studies have suggested a weak genetic association between PAD4 polymorphisms and susceptibility to RA (Kochi Y. et al., Ann. Rheum. Dis., 70, (2011), 512-515). PAD4 (along with its family member PAD2) has been detected in synovial tissue, where it is responsible for the deiminization of various joint proteins. This process is presumed to lead to the disruption of tolerance to citrullinated substrates, such as fibrinogen, vimentin, and collagen, in RA joints, and the initiation of immune responses against them. These anti-citrullinated protein antibodies (ACPAs) contribute to the pathogenesis of the disease and can also be used as diagnostic tests for RA (e.g., commercially available CCP2 or cyclic citrullinated protein 2 tests). Additionally, increased citrullination may provide an additional direct contribution to the pathogenesis through its ability to directly affect the function of various joint and inflammatory mediators (e.g., fibrinogen, antithrombin, and multiple chemokines). In a smaller subset of RA patients, anti-PAD4 antibodies can be measured and may correlate with a more erosive form of the disease.

[0007] PAD4 inhibitors are also useful for reducing pathological neutrophil activity in various diseases. Studies suggest that the process of forming neutrophil extracellular traps (NETs), an innate defense mechanism in which neutrophils can immobilize and kill pathogens, is associated with histone citrullination and is deficient in PAD4 knockout mice (Neeli I. et al., J. Immunol., 180, (2008), 1895-1902 and Li P. et al., J. Exp. Med., 207(9), (2010), 1853-1862). Therefore, PAD4 inhibitors may be applicable to diseases in which NET formation in tissues contributes to local injury and disease pathology. These diseases include small vessel vasculitis (Kessenbrock K. et al., Nat. Med., 15(6), (2009), 623-625), systemic lupus erythematosus (Hakkim A. et al., Proc. Natl. Acad. Sci. USA, 107(21), (2010), 9813-9818 and Villanueva E. et al., J. Immunol., 187(1), (2011), 538-52), ulcerative colitis (Savchenko A. et al., Pathol. Int., 61(5), (2011), 290-7), cystic fibrosis, asthma (Dworski R. et al., J. Allergy Clin. Immunol., 127(5), (2011), 1260-6), and deep vein thrombosis. (Fuchs T. et al., Proc. Natl. Acad. Sci. USA, 107(36), (2010), 15880-5), periodontitis (Vitkov L. et al., Ultrastructural Pathol., 34(1), (2010), 25-30), sepsis (Clark SR et al., Nat. Med., 13(4), (2007), 463-9), appendicitis (Brinkmann V. et al...., Science, 303, (2004), 1532-5) and stroke, including but not limited to these. Additionally, since there is evidence that NET may contribute to pathological conditions in skin-affecting diseases, e.g., cutaneous lupus erythematosus (Villanueva E. et al., J. Immunol., 187(1), (2011), 538-52) and psoriasis (Lin AM et al., J. Immunol., 187(1), (2011), 490-500), PAD4 inhibitors may show benefit in treating NET skin diseases when administered via systemic or cutaneous routes. PAD4 inhibitors affect additional functions within neutrophils and may have broader applicability to neutrophilic diseases.

[0008] Studies have demonstrated the efficacy of instrumental PAD inhibitors (e.g., chloroamidine) in a number of animal models of diseases including collagen-induced arthritis (Willis VC et al., J. Immunol., 186(7), (2011), 4396-4404), dextran sulfate sodium (DSS)-induced experimental colitis (Chumanevich AA et al., Am. J. Physiol. Gastrointest. Liver Physiol., 300(6), (2011), G929-G938), spinal cord repair (Lange S. et al., Dev. Biol., 355(2), (2011), 205-14) and experimental autoimmune encephalomyelitis (EAE). Reports on DSS colitis also demonstrate that chloroamidine induces apoptosis in inflammatory cells both in vitro and in vivo, suggesting that PAD4 inhibitors may be more generally effective in widespread inflammatory diseases.

[0009] PAD4 inhibitors are also useful in the treatment of cancer (Slack JL et al., Cell. Mol. Life Sci., 68(4), (2011), 709-720). Overexpression of PAD4 has been demonstrated in numerous cancers (Chang X. et al., BMC Cancer, 9, (2009), 40). An antiproliferative role for PAD4 inhibitors has been suggested from the observation that PAD4 citrullizes arginine residues within histones at the promoter of p53-target genes, such as p21, which are associated with the induction of cell cycle arrest and apoptosis (Li P. et al., Mol. Cell Biol., 28(15), (2008), 4745-4758).

[0010] The aforementioned role of PAD4 in deiminizing arginine residues within histones may indicate its role in the epigenetic regulation of gene expression. PAD4 is a major member of the PAD family observed to reside in the cytoplasm as well as the nucleus. Initial evidence regarding whether PAD4 acts as a deminase as well as a histone demethyliminase has been inconsistent and unproven. However, this may indirectly reduce histone arginine methylation (and thus epigenetic regulation associated with this mark) through the depletion of available arginine residues via conversion to citrulline. PAD4 inhibitors are useful as epigenetic tools or therapeutic agents to influence the expression of various target genes in additional disease settings. Through this mechanism, PAD4 inhibitors may also be effective in controlling citrullination levels in stem cells and thus therapeutically influence the pluripotency and differentiation potential of various stem cells, including but not limited to embryonic stem cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Therefore, there remains an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated diseases or disorders.

[0011] Accordingly, a compound of formula (Ia) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts are provided.

[0012]

[0013] In another general aspect, a pharmaceutical composition is provided comprising at least one compound of formula (I) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, and one or more pharmaceutically acceptable carriers.

[0014] In another general aspect, a method for treating a disease or disorder associated with PAD4 enzyme activity is provided, comprising administering a therapeutically effective amount of at least one compound of formula (I) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a subject who requires treatment for a disease or disorder associated with PAD4 enzyme activity.

[0015] Details of one or more embodiments of the present invention are set forth in the following description. Other features, objects, and advantages of the present invention will be apparent from the following description, including the claims. Specific details for implementing the invention

[0016] 1. Definition

[0017] The following are definitions of terms used in this specification. The initial definitions provided herein for a term or concept shall apply to such term or concept throughout the specification, either individually or as part of another term, unless otherwise indicated. It should be understood that while the invention has been described with reference to exemplary embodiments, there is no intention to limit the scope of the invention. Numerous modifications and further variations of the features of the invention may be conceived by those skilled in the art and are contained within this disclosure. All such modifications and variations shall be deemed to be within the scope of the invention. It should be noted that, as used in this specification and the appended claims, the singular form includes the plural designation unless the content otherwise expressly indicates otherwise. All references, including patents, patent applications, and literature cited in this specification, are expressly incorporated herein by reference in their entirety.

[0018] The term "C" used in this document 1-6 "Alkyl" refers to and includes cyclic, straight-chain, and branched-chain hydrocarbon groups containing 1 to 6 carbon atoms. C 1-6 Typical non-limiting examples of alkyls include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0019] As used herein, the term “alkenyl” refers to and includes straight-chain or branched-chain hydrocarbon groups containing 2 to 20 carbons and containing 1 to 6 double bonds. Typical non-limiting examples of alkenyls include vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, etc.

[0020] As used herein, the term "alkynyl" refers to and includes straight-chain or branched-chain hydrocarbon groups containing 2 to 12 carbon atoms and at least one carbon-to-carbon triple bond. Typical, non-limiting examples of alkynyl include ethinyl, 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexinyl, 3-hexinyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octinyl, 3-noninyl, 4-decinyl, etc.

[0021] As used herein, the term "cycloalkyl" refers to and includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings (e.g., monocyclic, noncyclic, or tricyclic) and a total of 3 to 20 carbon atoms forming the rings. Cycloalkyl groups may be optionally substituted. The rings of the polycyclic cycloalkyl may exist as being connected to 1 or 2 aromatic cycloalkyl or heterocyclic rings via fusion, crosslinking, and / or one or more spiro bonds. Typical, non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, cycloheptadienyl, etc.

[0022] As used herein, the terms “heterocyclic,” “heterocyclil,” or “heterocyclo” refer to and include optionally substituted, saturated, unsaturated, or partially unsaturated 3 to 20-membered cyclic groups (e.g., 3 to 13-membered monocyclic, 7 to 17-membered biccyclic, or 10 to 20-membered tricyclic ring systems) having at least one heteroatom within at least one carbon atom-containing ring. The heteroatom is selected from nitrogen, oxygen, and / or sulfur atoms. Each ring of the heterocyclic group may have 1, 2, 3, 4, or 5 heteroatoms, provided that at least one ring contains at least one heteroatom. The nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The rings of a multi-ring heterocycle can be connected through fusion, crosslinking, and / or one or more spiro bonds. Typical, non-limiting examples of heterocyclic groups include azetidinyl, pyrrolidinyl, oxetanil, imidazolinil, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranil, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazefinil, azefinil, 4-piperidonyl, tetrahydropyranil, morpholinyl, thiamofolinyl, thiamofolinyl sulfoxide, thiamofolinyl sulfone, 1,3-dioxolane, and tetrahydro-1,1-dioxothienyl, etc.

[0023] As used herein, the term "aryl" refers to an aromatic homocyclic (i.e., hydrocarbon) monocyclic, bicyclic, or tricyclic aromatic group containing 6 to 14 carbons in the ring portion, and may optionally include 1 to 3 additional rings (cycloalkyl, heterocyclo, or heteroaryl) fused thereto. Typical, non-limiting examples of aryl groups include phenyl, biphenyl, naphthyl (including 1-naphthyl and 2-naphthyl), anthracenyl, etc.

[0024] One or more hydrogen atoms attached to a carbon atom may be optionally substituted with any group known to a person skilled in the art. Throughout the specification, the group and its substituents may be selected to provide a stable moiety and compound.

[0025] As used herein, the term "subject" refers to and includes any human or non-human organism that may potentially benefit from treatment with a PAD4 inhibitor. Exemplary subjects include humans and animals.

[0026] As used herein, the terms “treating” or “treatment” refer to and include the treatment of a disease-state in a subject, e.g., a human or animal, comprising (a) suppressing the disease-state, i.e., stopping its occurrence; (b) alleviating the disease-state, i.e., causing the regression of the disease-state; and / or (c) preventing the occurrence of the disease-state in the subject.

[0027] As used herein, the terms “preventive” or “preventive” refer to and include the prophylactic treatment (i.e., prevention and / or risk reduction) of a subclinical disease-state in subjects, e.g., humans or animals, aimed at reducing the probability of occurrence of a clinical disease-state. Subjects may be selected for prophylactic therapy based on factors known to increase the risk of developing a clinical disease-state compared to the general population. “Preventive” therapy may be divided into (a) primary prevention and (b) secondary prevention. Primary prevention is defined as treatment in subjects who have not yet exhibited a clinical disease-state, whereas secondary prevention is defined as preventing a second occurrence of the same or similar clinical disease-state.

[0028] The term "therapeutic effective dose" refers to and includes the amount of a compound or composition according to the present invention that is effective when administered alone or in combination to prevent or treat diseases or disorders associated with PAD4 enzyme activity. When applied to a combination, the term refers to the sum of the active ingredients that produce a preventive or therapeutic effect, regardless of whether they are combined and administered sequentially or simultaneously.

[0029] "Pharmaceutical acceptable carriers" refers to media generally accepted in the art for delivering biologically active agents to humans and / or animals. Pharmaceutically acceptable carriers are well formulated according to a number of factors within the understanding of a person skilled in the art. These include, but are not limited to, the type and nature of the active agent being formulated, the subjects to whom the agent-containing composition is to be administered, the intended route of administration of the compound or composition, and the therapeutic indications to be targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media. Such carriers may contain a number of different components and additives in addition to the active agent, and these additional components are included in the formulation for various reasons widely known to a person skilled in the art, e.g., for stabilizing the active agent, binder, etc. Typical, non-limiting examples of such carriers include diluents, preservatives, fillers, flow control agents, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, perfumes, antibacterial agents, antifungal agents, lubricants, dispensing agents, coating agents, etc. Descriptions of suitable pharmaceutically acceptable carriers and the factors involved in their selection are found in various readily available sources, such as, for example, the literature [Allen, LV, Jr. et al., Remington: The Science and Practice of Pharmacy (2 Volumes), 22nd Edition, Pharmaceutical Press (2012)].

[0030] The prodrugs and solvates of the compounds of the present invention are also considered herein. As used herein, the term "prodrug" refers to a compound that, upon administration to a subject, undergoes a chemical transformation by metabolic or chemical processes to yield a compound of formula (I) or its salt and / or solvate. Solvents of the compound of formula (Ia) include hydrates.

[0031] Any tautomers that may exist are also considered herein as part of the invention. All stereoisomers of the compound of formula (Ia), such as those that may exist due to an asymmetric carbon, such as enantiomer forms (which may exist in the absence of an asymmetric carbon, e.g., rotationally hindered isomers) and diastereomer forms, are considered within the scope of the invention. Individual stereoisomers of the compound of formula (Ia) may, for example, be substantially absent from other isomers, or may be mixed with all other or other selected stereoisomers, for example as a racemic mixture. In these compounds, the chiral center may have an S or R coordination as defined by the IUPAC 1974 recommendations. In general, compounds according to the invention may be described herein without specific stereochemistry for convenience, but all stereoisomer forms are included within the scope of the invention.

[0032] The present invention is intended to include all isotopes of atoms occurring in the compounds of the present invention. Isotopes include atoms having the same atomic number but different mass numbers. As a general example and without limitation, isotopes of hydrogen include deuterium (symbol D or 2 H) and tritium (symbol T or 3 It includes H). For example, the methyl group can be represented as CH3 or CD3. Isotopes of carbon are 13 C and 14Includes C. The isotope-labeled compounds of the present invention may be prepared by using a suitable isotope-labeled reagent instead of an otherwise used unlabeled reagent by conventional techniques generally known to those skilled in the art or by methods similar to those described herein.

[0033] The compound of formula (I) also forms a salt within the scope of the present invention. Unless otherwise indicated, references to the compound of formula (I) in this invention are understood to include references to its salt. As used herein, the term “salt(s)” refers to acidic and / or basic salts formed using inorganic and / or organic acids and bases. Additionally, where the compound of formula (I) contains both a basic moiety and an acidic moiety, a zwitterion (“internal salt”) may be formed, which is included within the term “salt(s)” as used herein. Pharmaceutically acceptable salts include those generally accepted in the field of pharmaceutical science for administration to subjects including humans and animals. Generally, pharmaceutically acceptable salts are non-toxic and physiologically acceptable salts. Salts of the compounds according to the present invention may be formed by reacting the compound with a predetermined amount, e.g., an equivalent amount of acid or base, in a medium such as one that precipitates salts, or in an aqueous medium, and then freeze-drying.

[0034] Compounds of chemical formula (Ia) containing a basic moiety can form salts with various organic and inorganic acids. Exemplary acid addition salts include acetates (e.g., those formed by acetic acid or trihaloacetic acids, e.g., trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecyl sulfate, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfate, heptanoates, hexanoates, hydrochlorides (formed by hydrochloric acid), hydrobromides (formed by hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed by maleic acid), and methanesulfonates (formed by methanesulfonic acid It includes 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (e.g., those formed by sulfuric acid), sulfonate (e.g., those mentioned herein), tartrate, thiocyanate, toluenesulfonate such as tosylate, undecanoate, etc.

[0035] Compounds of formula (Ia) containing an acidic moiety can form salts with various organic and inorganic bases. Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, organic bases (e.g., organic amines) such as benzathine, dicyclohexylamine, hydravamin (formed from N,N-bis(dehydroaviethyl)-ethylenediamine), N-methyl-D-glucarmine, N-methyl-D-glucamide, t-butylamine, and salts with amino acids such as arginine, lysine, etc. Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl and butyl chloride, bromide and iodide), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl and diamyl sulfates), long-chain halides (e.g., decyl, lauryl, myristyl and stearyl chloride, bromide and iodide), aralkyl halides (e.g., benzyl and phenethyl bromide), etc.

[0036] The present invention comprises compounds of formula (I) (including their stereoisomers, enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts), methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and the use of these compounds in the treatment of diseases or disorders associated with PAD4 enzyme activity.

[0037] 2. Description of specific aspects of the present invention

[0038] In a first aspect, the present invention provides a compound of the following formula (I) or a salt thereof that is pharmaceutically acceptable:

[0039]

[0040] Here

[0041] is independently Selected from;

[0042] X1 and X2 are independently selected from CH and N;

[0043] X3 is independently selected from O and S;

[0044] X4 is independently selected from CR2 and N; provided that X1 and X4 are not both N;

[0045] R1 is independently -NH-C optionally substituted with one or more substituents selected from F, Cl, and NH2. 1-5 Selected from alkyl, 4-10-membered heterocyclyl, and -NH-4-10-membered heterocyclyl, wherein the heterocyclyl is F, Cl, CN, C 1-3 Alkyl, =N-OR b , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=NH)C 1-3 Alkyl, -NR a C(=O)OR b Optionally substituted with one or more substituents selected from , carbocyclil, and heterocyclil;

[0046] R2 independently contains H, F, Cl, and C 1-4 Alkyl, and -OC 1-4 Selected from alkyls;

[0047] R3 is independently H, F, Cl, -CN, -C(=O)OR b , and C optionally substituted with one or more substituents selected from F, Cl, and OH. 1-3 Selected from alkyls;

[0048] R4 is independently H, F, Cl, Br, -C(=O)R b ; C optionally substituted with one or more substituents selected from F, Cl, and -OH 1-6 Alkyl; -NH-C optionally substituted with one or more substituents selected from F, Cl, and OH 1-6 Alkyl, and C3-6 Cycloalkyl, -(CH2) substituted with one or more R5s r -aryl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0049] R5 is independently H, F, Cl, Br, -CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkinyl, -(CR d R d ) r OR b , -(CR d R d ) r S(O) p R c , -(CR d R d ) r S(O) p NR a R a , -(CR d R d ) r NR a S(O) p R c , -(CR d R d ) r NR a R a , -(CR d R d ) r NR a C(=O)R b , -(CR d R d ) r NR a C(=O)OR b , -(CRd R d ) r NR a C(=O)NR a R a , -(CR d R d ) r C(=O)R b , -(CR d R d ) r C(=O)OR b , -(CR d R d ) r C(=O)NR a R a , -(CR d R d ) r OC(=O)R b , -(CR d R d ) r OC(=O)OR b , -(CR d R d ) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0050] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R eAn aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0051] R7 is independently selected from H, F, and Cl;

[0052] R8 independently H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0053] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0054] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e-(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0055] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-6 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0056] R d is independently H, 1 or more R e C arbitrarily substituted as 1-6 Selected from alkyls,

[0057] R e are independently F, Cl, Br, -CN, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -Aryl, 1 or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0058] R f C independently substituted with F, Cl, Br, -CN, -OH, -OH1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0059] p is independently selected from 0, 1, and 2 in each case;

[0060] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0061] In a second aspect, the present invention provides, within the scope of the first aspect, a compound of formula (II) or a salt thereof that is permitted by the constraints:

[0062]

[0063] Here

[0064] X2 is independently selected from CH and N;

[0065] R1 independently

[0066]

[0067] Selected from;

[0068] R2 is independently selected from H, F, Cl, -CH3, and -OCH3;

[0069] R3 is independently selected from H, F, Cl, -CN, -CH3, and -CH2OH;

[0070] R4 is independently C optionally substituted with one or more substituents selected from H; F, Cl, and -OH. 1-5 Alkyl, phenyl substituted with one or more R5-cycloalkyl groups, C 3-6 Selected from 4-10 member heterocyclils comprising a cycloalkyl, and 1-5 heteroatoms selected from a carbon atom and N, NR6, O, and S, and substituted with one or more R5s;

[0071] R5 is independently H, F, Cl, Br, -CN, =O, and one or more R e C arbitrarily substituted as1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenil, -(CHR d ) r OR b , -(CHR d ) r S(O) p R c -(CHR d ) r NR a S(O) p R c , -(CHR d ) r NR a R a , -(CHR d ) r NR a C(=O)R b , -(CHR d ) r NR a C(=O)OR b , -(CHR d ) r C(=O)R b , -(CHR d ) r C(=O)OR b , -(CHR d ) r C(=O)NR a R a , -(CHR d ) r OC(=O)R b , -(CHR d ) r OC(=O)OR b , -(CHR d ) r O(CH2) r C(=O)NR a R a Selected from;

[0072] R6 independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0073] R8 independently H and -CH2-C 3-6Selected from cycloalkyl;

[0074] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0075] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0076] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-6 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0077] R d is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0078] R eis independently F, Cl, Br, -CN, -NO2, =O, OH, OC 1-4 Alkyl, one or more R f C arbitrarily substituted as 1-4 Alkyl, one or more R f C arbitrarily substituted as 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -Aryl, 1 or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0079] R f is independently selected from F, Cl, Br, -CN, and -OH;

[0080] p is independently selected from 0, 1, and 2 in each case;

[0081] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0082] In a third aspect, the present invention, within the scope of the second aspect,

[0083] R1 independently

[0084]

[0085] Selected from;

[0086] R2 is independently selected from H, F, -CH3, and -OCH3;

[0087] R3 is independently selected from H, Cl, -CH3, and -CH2OH;

[0088] R4 is independently C optionally substituted with one or more substituents selected from H; F, Cl, and -OH. 1-5 Alkyl, phenyl substituted with one or more R5 groups, C 3-6 Selected from 4-10 member heterocyclils comprising a cycloalkyl, and 1-5 heteroatoms selected from a carbon atom and N, NR6, O, and S, and substituted with one or more R5s;

[0089] R5 is H, F, Cl, -CN, =O, and one or more R's independently in each case e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , and -(CH2) r O(CH2) r C(=O)NR a R a Selected from;

[0090] R6 independently H, and one or more R e C arbitrarily substituted as 1-3 Selected from alkyls;

[0091] R8 is -CH2-cyclopropyl;

[0092] R a is independently H, and one or more R e C arbitrarily substituted as 1-6Selected from alkyls; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0093] R b is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls;

[0094] R c is one or more R e C arbitrarily substituted as 1-6 It is alkyl;

[0095] R e is independently F, Cl, Br, -CN, =O, OH, OC 1-3 Alkyl, one or more R f C arbitrarily substituted as 1-3 Alkyl, one or more R f C arbitrarily substituted as 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -Aryl, 1 or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0096] R f is independently selected from F, Cl, Br, -CN, and -OH;

[0097] p is independently selected from 0, 1, and 2 in each case;

[0098] r is selected independently from 0, 1, 2, 3, and 4 in each case

[0099] Provides a compound or a salt that is pharmaceutically acceptable thereto.

[0100] In a fourth aspect, the present invention within the scope of the third aspect,

[0101] R1 independently Selected from;

[0102] R2 is independently selected from H, F, and -OCH3;

[0103] R3 is CH3 and;

[0104] R4 is F, Cl, C 1-3 alkyl,

[0105]

[0106]

[0107]

[0108] Selected from;

[0109] R5 is H, F, Cl, -CN, =O, and one or more R's independently in each case e C arbitrarily substituted as 1-4 alkyl, -OR b , -NR a S(O)2R c , -NR a R a , -NR a C(=O)R b , -NR a C(=O)OR b , -NR a C(=O)NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , -OC(=O)R b , and -OC(=O)OR b Selected from;

[0110] R6 independently H and C 1-3 Selected from alkyls;

[0111] R a H and C independently 1-5 Selected from alkyls; or R a and R a is one or more R together with the nitrogen atom to which both are attached. eForming a heterocyclic ring arbitrarily substituted with;

[0112] R b is independently H, and one or more R e C arbitrarily substituted as 1-5 Selected from alkyls;

[0113] R c is one or more R e C arbitrarily substituted as 1-5 It is alkyl;

[0114] R e is independently F, Cl, Br, -CN, =O, OH, one or more R f C arbitrarily substituted as 1-4 Alkyl, one or more R f C arbitrarily substituted as 3-6 Cycloalkyl, one or more R f An aryl arbitrarily substituted with , one or more R f Selected from heterocyclils arbitrarily substituted with;

[0115] R f is independently selected from F, Cl, Br, -CN, and -OH

[0116] Provides a compound or a salt that is pharmaceutically acceptable thereto.

[0117] In a fifth aspect, the present invention within the scope of the fourth aspect,

[0118] R4 is C 1-2 alkyl,

[0119]

[0120] Selected from;

[0121] R5 is H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 alkyl, -OR b , -NR a S(O)2R c -NR a R a , -NR a C(=O)R b, and C(=O)NR a R a Selected from;

[0122] R6 is independently C optionally substituted with H, and one or more substituents selected from F, Cl, and OH. 1-4 Selected from alkyls;

[0123] R a is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0124] R b is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0125] R c is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0126] R e is independently F, Cl, Br, -CN, =O, OH, and C 1-6 selected from alkyl

[0127] Provides a compound or a salt that is pharmaceutically acceptable thereto.

[0128] In a sixth aspect, the present invention within the scope of the fifth aspect,

[0129] R4 independently CH3,

[0130]

[0131] Selected from;

[0132] R5 is independently selected from F, Cl, -OH, and C(=O)NH2

[0133] Provides a compound or a salt that is pharmaceutically acceptable thereto.

[0134] In a seventh aspect, the present invention provides, within the scope of the first aspect, a compound of formula (III) or a salt thereof that is permitted by the constraints:

[0135]

[0136] Here

[0137] X2 is independently selected from CH and N;

[0138] R1 independently Selected from;

[0139] R2 is independently selected from H, F, Cl, -CH3, and -OCH3;

[0140] R3 is independently selected from H, F, Cl, -CN, -CH3, and -CH2OH;

[0141] R4 independently contains H, F, Cl, and C 1-3 alkyl,

[0142]

[0143] Selected from;

[0144] R5 independently contains H, F, Cl, =O, -OH, -OCHF2, C(=O)NH2, and -NHS(O)2C 1-4 Selected from alkyls;

[0145] R6 is independently C optionally substituted with H, and one or more substituents selected from F, Cl, and OH. 1-4 Selected from alkyls;

[0146] R8 is -CH2-cyclopropyl;

[0147] R a is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0148] R b is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0149] R e is independently F, Cl, Br, -CN, =O, OH, and C 1-6 Selected from alkyls.

[0150] In an eighth aspect, the present invention provides, within the scope of the first aspect, a compound of formula (IV) or a salt thereof that is pharmaceutically acceptable:

[0151]

[0152] Here

[0153] X2 is independently selected from CH and N;

[0154] R1 independently -NHCH2CHFCH2NH2,

[0155]

[0156] Selected from;

[0157] R2 is independently selected from H, F, Cl, -CH3, and -OCH3;

[0158] R3 is independently selected from H, F, Cl, -CN, -CH3, and -CH2OH;

[0159] R4 independently contains H, F, Cl, and C 1-3 Selected from alkyls;

[0160] R8 is -CH2-cyclopropyl.

[0161] In a ninth aspect, the present invention provides, within the scope of the first aspect, a compound of formula (V) or a salt thereof that is permitted by the constraints:

[0162]

[0163] Here

[0164] X2 is independently selected from CH and N;

[0165] R1 independently Selected from;

[0166] R2 is independently selected from H, F, Cl, -CH3, and -OCH3;

[0167] R3 is independently selected from H, F, Cl, -CN, -CH3, and -CH2OH;

[0168] R4 independently contains H, F, Cl, Br, and C 1-3 alkyl,

[0169]

[0170] Selected from;

[0171] R5 is independently selected from H, F, Cl, =O, -OH, -OCHF2, NH2, and C(=O)NH2;

[0172] R6 is independently C optionally substituted with H, and one or more substituents selected from F, Cl, and OH. 1-4 Selected from alkyls;

[0173] R8 is -CH2-cyclopropyl;

[0174] R a is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0175] R b is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0176] R e is independently F, Cl, Br, -CN, =O, OH, and C 1-6 Selected from alkyls.

[0177] In a tenth aspect, the present invention provides, within the scope of the first aspect, a compound of formula (VI) or a salt thereof that is pharmaceutically acceptable:

[0178]

[0179] Here

[0180] X2 is independently selected from CH and N;

[0181] R1 independently Selected from;

[0182] R2 is independently selected from H, F, Cl, -CH3, and -OCH3;

[0183] R3 is independently selected from H, F, Cl, -CN, -CH3, and -CH2OH;

[0184] R4 independently contains H, F, Cl, and C 1-3 alkyl,

[0185]

[0186] Selected from;

[0187] R5 is independently selected from H, F, Cl, =O, -OH, -OCHF2, and -C(=O)NH2;

[0188] R6 is independently C optionally substituted with H, and one or more substituents selected from F, Cl, and OH. 1-4 Selected from alkyls;

[0189] R8 is -CH2-cyclopropyl;

[0190] R a is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0191] R b is independently H, and one or more R e C arbitrarily substituted as 1-4 Selected from alkyls;

[0192] R e is independently F, Cl, Br, -CN, =O, OH, and C 1-6 Selected from alkyls.

[0193] In the eleventh aspect, the present invention within the scope of the tenth aspect,

[0194] R1 independently Selected from;

[0195] R2 is independently selected from H, F, and -OCH3;

[0196] R3 is -CH3 and;

[0197] R4 is independently Selected from;

[0198] R5 is independently F, Cl, -OH, -NH2, -OC 1-4 alkyl, and selected from C(=O)NH2

[0199] Provides a compound or a salt that is pharmaceutically acceptable thereto.

[0200] In one aspect, the present invention provides a compound of formula (Ia) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0201]

[0202] Here

[0203] Is Selected from;

[0204] Is Selected from;

[0205] X1 is independently selected from CR2 and N;

[0206] X2 is independently selected from CR4 and N;

[0207] X3 is independently selected from O and S;

[0208] X4 is independently selected from CR2 and N; provided that X1 and X4 are not both N;

[0209] X5 is independently selected from O and S;

[0210] X6 is independently selected from CR4 and N; provided that 1) X2 and X6 are not both N; and 2) if X2 and X6 are both CR4, one of R4 is H;

[0211] R1 is independently -NH-C optionally substituted with one or more substituents selected from F, Cl, and NH2. 1-5 Selected from alkyl, 4-10-membered heterocyclyl, and -NH-4-10-membered heterocyclyl, wherein the heterocyclyl is F, Cl, CN, C 1-3 Alkyl, =N-OR b , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=NH)C 1-3 Alkyl, -NR a C(=O)OR b Optionally substituted with one or more substituents selected from , carbocyclil, and heterocyclil;

[0212] R2 is independently C optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH. 1-4 Alkyl, and -OC 1-4 Selected from alkyls;

[0213] R3 is independently H, F, Cl, CN, -C(=O)OR b , and C optionally substituted with one or more substituents selected from F, Cl, OH, NH2, and N3 1-3 Selected from alkyls;

[0214] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0215] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkinyl, -(CR d R d ) r OR b , -(CR d R d ) r S(O) p R c , -(CR d R d ) r S(O) p NR a R a , -(CR d R d ) r NR a S(O) p R c , -(CR d R d ) r NR a R a , -(CR d R d ) r NR a C(=O)R b , -(CR d R d ) r NR aC(=O)OR b , -(CR d R d ) r NR a C(=O)NR a R a , -(CR d R d ) r C(=O)R b , -(CR d R d ) r C(=O)OR b , -(CR d R d ) r C(=O)NR a R a , -(CR d R d ) r OC(=O)R b , -(CR d R d ) r OC(=O)OR b , -(CR d R d ) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0216] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0217] R7 is independently selected from H, F, and Cl;

[0218] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0219] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0220] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more Re -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0221] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0222] R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls;

[0223] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0224] R fis independently F, Cl, Br, CN, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0225] p is independently selected from 0, 1, and 2 in each case;

[0226] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0227] In another aspect, the present invention provides a compound of formula (IIa)-(XIII) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0228]

[0229] Here

[0230] R1, R2, R3, R4, R7, and R8 are as defined in chemical formula (Ia).

[0231] In another aspect, the present invention provides a compound having the formula (IIa) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0232]

[0233] Here

[0234] R1 independently

[0235]

[0236] Selected from;

[0237] R2 is independently C optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH. 1-3 Alkyl, and OC 1-3 Selected from alkyls;

[0238] R3 is independently selected from H, F, Cl, CH3, and CH2OH;

[0239] R4 independently contains H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0240] R5 is independently H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2)r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0241] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, C(=O)R b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0242] R7 is independently selected from H, F, and Cl;

[0243] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0244] R ais independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0245] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0246] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0247] R e is independently F, Cl, Br, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f-(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0248] R f is independently F, Cl, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 3-6 Selected from cycloalkyl and phenyl;

[0249] p is independently selected from 0, 1, and 2 in each case;

[0250] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0251] In another aspect, the present invention provides a compound having the formula (IIIa) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0252]

[0253] Here

[0254] R1 independently

[0255]

[0256] Selected from;

[0257] R2 is independently C optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH. 1-3 Alkyl, and OC 1-3 Selected from alkyls;

[0258] R3 is independently C optionally substituted with one or more substituents selected from H, F, Cl, and F, Cl, and OH. 1-3 Selected from alkyls;

[0259] R4 independently contains H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0260] R5 is independently H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a Ra , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0261] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0262] R7 is independently selected from H, F, and Cl;

[0263] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0264] R a is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls; or R a and R a is one or more R together with the nitrogen atom to which both are attached. eForming a heterocyclic ring arbitrarily substituted with;

[0265] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0266] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0267] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0268] R f is independently F, Cl, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C3-6 Selected from cycloalkyl and phenyl;

[0269] p is independently selected from 0, 1, and 2 in each case;

[0270] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0271] In another aspect, the present invention

[0272] R1 independently Selected from;

[0273] R2 is independently selected from H, F, Cl, CH3, and OCH3;

[0274] R3 is independently selected from H, F, Cl, CH3, and CH2OH;

[0275] R4 independently consists of H, F, Cl; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-5 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0276] R5 is independently H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O)2R c , -(CH2) r S(O) p NR a R a , -(CH2)r NR a S(O)2R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0277] R6 independently H and one or more R e C arbitrarily substituted as 1-65 Selected from alkyls;

[0278] R7 is H;

[0279] R8 is 1 C 3-6 C substituted with a cycloalkyl group 1-3 It is alkyl;

[0280] R a H and C independently 1-4 Selected from alkyls;

[0281] R b is independently H, C 1-4 Selected from alkyls;

[0282] R c is C 1-4 It is alkyl;

[0283] r is selected independently from 0, 1, and 2 in each case

[0284] Provides a compound having the chemical formulas (IIa)-(IIIa) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0285] In another aspect, the present invention

[0286] R4 is independently C optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH. 1-5 Alkyl, C 3-6 cycloalkyl,

[0287]

[0288]

[0289]

[0290] Selected from;

[0291] R5 is independently H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2)r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0292] R6 independently H and C 1-5 Selected from alkyls; other variable groups are those defined in formulas (IIa)-(IIIa).

[0293] Provides a compound having the chemical formulas (IIa)-(IIIa) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0294] In another aspect, the present invention

[0295] R4 is independently

[0296]

[0297]

[0298]

[0299]

[0300] Selected from; other variable groups are those defined in formulas (IIa)-(IIIa).

[0301] Provides a compound having the chemical formulas (IIa)-(IIIa) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0302] In another aspect, the present invention provides a compound having the formula (IVa) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0303]

[0304] Here

[0305] R1 independently

[0306]

[0307] Selected from;

[0308] R2 is independently C optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH. 1-3 Alkyl, and OC 1-3 Selected from alkyls;

[0309] R3 is independently C optionally substituted with one or more substituents selected from H, F, Cl, and F, Cl, and OH. 1-3 Selected from alkyls;

[0310] R4 independently contains H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0311] R5 is independently H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)ORb , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0312] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0313] R7 is independently selected from H, F, and Cl;

[0314] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0315] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted asr - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0316] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0317] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0318] R e is independently F, Cl, Br, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0319] R f is independently F, Cl, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0320] p is independently selected from 0, 1, and 2 in each case;

[0321] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0322] In another aspect, the present invention

[0323] R1 independently Selected from;

[0324] R2 is independently selected from H, F, Cl, and OCH3;

[0325] R3 is independently selected from F, Cl, and CH3;

[0326] R4 independently H,

[0327]

[0328] Selected from;

[0329] R5 independently H, =O, C 1-4 Selected from alkyl, OH, and NH2;

[0330] R6 independently H, 1 or more R e C arbitrarily substituted as 1-5 Alkyl, and -C(=O)R b Selected from;

[0331] R7 is H;

[0332] R8 is C arbitrarily substituted with cyclopropyl 1-2 It is alkyl;

[0333] R b is independently H, 1 or more R eC arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0334] R e is independently NH2, and one or more R f C arbitrarily substituted as 1-5 Selected from alkyls;

[0335] R f is independently F, Cl, OH, and OC 1-5 selected from alkyl

[0336] Provides a compound having the chemical formula (IVa) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0337] In another aspect, the present invention

[0338] R4 is independently

[0339]

[0340]

[0341] Selected from; other variable groups are those defined in formulas (IIa)-(IIIa).

[0342] Provides a compound having the chemical formulas (IIa)-(IIIa) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0343] In another aspect, the present invention provides a compound having the formula (Va) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0344]

[0345] Here

[0346] R1 independently Selected from;

[0347] R2 is independently selected from H, F, Cl, CH3, and OCH3;

[0348] R3 is independently selected from H, F, Cl, CN, CH3, and CH2OH;

[0349] R4 independently contains H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0350] R5 is independently H, F, Cl, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) rNR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0351] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0352] R7 is independently selected from H, F, and Cl;

[0353] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0354] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0355] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0356] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0357] R eis independently F, Cl, Br, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0358] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0359] p is independently selected from 0, 1, and 2 in each case;

[0360] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0361] In another aspect, the present invention

[0362] R1 independently Selected from;

[0363] R2 is CH3 and;

[0364] R3 is CH3 and;

[0365] R4 is independently

[0366]

[0367] Selected from;

[0368] R7 is H;

[0369] R8 is C arbitrarily substituted with cyclopropyl 1-2 alkyl phosphorus

[0370] Provides a compound having the chemical formula (Va) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0371] In another aspect, the present invention provides a compound having the formula (VIa) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0372]

[0373] Here

[0374] R1 independently Selected from;

[0375] R3 is independently selected from H, F, and CH3;

[0376] R4 independently contains H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0377] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0378] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0379] R7 is independently selected from H, F, and Cl;

[0380] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0381] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0382] R b is independently H, 1 or more R eC arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0383] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0384] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f-(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0385] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0386] p is independently selected from 0, 1, and 2 in each case;

[0387] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0388] In another aspect, the present invention

[0389] R1 independently Selected from;

[0390] R3 is CH3 and;

[0391] R4 independently F, Cl,

[0392]

[0393]

[0394] Selected from;

[0395] R7 is H;

[0396] R8 is C arbitrarily substituted with cyclopropyl 1-2 alkyl phosphorus

[0397] Provides a compound having the chemical formula (VIa) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0398] In another aspect, the present invention provides a compound having the formula (VII) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts:

[0399]

[0400] Here

[0401] R1 independently Selected from;

[0402] R2 is independently selected from H, F, Cl, CH3, and OCH3;

[0403] R3 is independently selected from H, F, and CH3;

[0404] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0405] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O)p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0406] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NRa R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0407] R7 is independently selected from H, F, and Cl;

[0408] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0409] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0410] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rse -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0411] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0412] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0413] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0414] p is independently selected from 0, 1, and 2 in each case;

[0415] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0416] In another aspect, the present invention provides a compound having the formula (VIII) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts:

[0417]

[0418] Here

[0419] R1 independently Selected from;

[0420] R2 is independently selected from H, F, and OCH3;

[0421] R3 is independently selected from H, F, and CH3;

[0422] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s rSelected from -4-10 month heterocyclils;

[0423] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R eC arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0424] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0425] R7 is independently selected from H, F, and Cl;

[0426] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0427] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R ais one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0428] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0429] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0430] R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls;

[0431] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0432] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0433] p is independently selected from 0, 1, and 2 in each case;

[0434] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0435] In another aspect, the present invention provides a compound having the following formula (IX) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0436]

[0437] Here

[0438] R1 independently Selected from;

[0439] R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, and OCH3;

[0440] R3 is independently selected from H, F, Cl, CH3, CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3;

[0441] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0442] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NRa R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0443] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R eSelected from heterocyclils arbitrarily substituted with;

[0444] R7 is independently selected from H, F, and Cl;

[0445] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0446] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0447] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0448] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0449] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0450] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0451] p is independently selected from 0, 1, and 2 in each case;

[0452] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0453] In another aspect, the present invention provides a compound of formula (X) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0454]

[0455] Here

[0456] R1 independently Selected from;

[0457] R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, and OCH3;

[0458] R3 is independently selected from H, F, CH3,CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3;

[0459] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0460] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R eAn aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0461] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0462] R7 is independently selected from H, F, and Cl;

[0463] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0464] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R ais one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0465] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0466] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0467] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rsf -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0468] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0469] p is independently selected from 0, 1, and 2 in each case;

[0470] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0471] In another aspect, the present invention provides a compound having the formula (XI) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0472]

[0473] Here

[0474] R1 independently Selected from;

[0475] R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, and OCH3;

[0476] R3 is independently selected from H, F, CH3CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3;

[0477] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0478] R5 is independently H, F, Cl, Br, CN, =O, and one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NRa C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0479] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0480] R7 is independently selected from H, F, and Cl;

[0481] R8 independently contains H, and F, Cl, and C 3-6C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0482] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0483] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0484] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0485] R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls;

[0486] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0487] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0488] p is independently selected from 0, 1, and 2 in each case;

[0489] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0490] In another aspect, the present invention provides a compound having the formula (XII) or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt:

[0491]

[0492] Here

[0493] R1 independently Selected from;

[0494] R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH and OCH3;

[0495] R3 is independently selected from H, F, CH3CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3;

[0496] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0497] R5 is independently H, F, Cl, Br, CN, =O, and one or more Re C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R eSelected from heterocyclils arbitrarily substituted with;

[0498] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0499] R7 is independently selected from H, F, and Cl;

[0500] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0501] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R ais one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0502] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0503] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0504] R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls;

[0505] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0506] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0507] p is independently selected from 0, 1, and 2 in each case;

[0508] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0509] In another aspect, the present invention

[0510] R4 independently contains H, F, Cl, Br,

[0511]

[0512]

[0513]

[0514]

[0515] Selected from; other variable groups are those defined in formulas (IX)-(XII).

[0516] Provides a compound having chemical formulas (IX)-(XII) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0517] In another aspect, the present invention provides a compound having the formula (XIII) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts:

[0518]

[0519] Here

[0520] R1 independently Selected from;

[0521] R2 is independently selected from H, F, CH3, and OCH3;

[0522] R3 is independently selected from H, F, and CH3;

[0523] R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10 month heterocyclils;

[0524] R5 is independently H, F, Cl, Br, CN, =O, and one or more R eC arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R eSelected from heterocyclils arbitrarily substituted with;

[0525] R6 independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0526] R8 independently contains H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyls;

[0527] R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;

[0528] R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclils;

[0529] R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0530] R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls;

[0531] R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclils;

[0532] R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl and phenyl;

[0533] p is independently selected from 0, 1, and 2 in each case;

[0534] r is independently selected from 0, 1, 2, 3, and 4 in each case.

[0535] In another aspect, the present invention provides a compound having the formula (XIV) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts:

[0536]

[0537] Here

[0538] X2 is independently selected from CR4 and N;

[0539] X3 is independently selected from O and S;

[0540] R1 independently Selected from;

[0541] R2 is independently selected from CH2OH, CH2CH2OH and OCH3;

[0542] R3 is independently selected from CH2OH, CH2CH2OH, CH2NH2, CH2CH2NH2, and CH2CH2N3;

[0543] R4 is independently substituted with H and one or more R5s, -OC 1-4 Selected from alkyls; provided that both R4s are substituted with one or more R5s -OC 1-4 It is not alkyl;

[0544] R5 independently OH, and one or more R e Selected from heterocyclils arbitrarily substituted with;

[0545] R8 independently H, and C 3-6 C optionally substituted with a cycloalkyl 1-6 Selected from alkyls;

[0546] R e is independently NH2 and C 1-3 Selected from alkyls.

[0547] In another aspect, the present invention provides a compound having the formula (XV) or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[0548]

[0549] Here

[0550] R4 independently H, OCH3, OCH2CH2OH,

[0551]

[0552] Selected from;

[0553] R8 is C 3-6 C substituted with a cycloalkyl group 1-3 It is alkyl;

[0554] R e is independently NH2 and C 1-3 Selected from alkyls; other variable groups are as defined in formula (XIV).

[0555] Typical non-limiting examples of compounds according to the present invention include the following:

[0556] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (1);

[0557] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (2);

[0558] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (3);

[0559] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (4);

[0560] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]-heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (5);

[0561] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (6);

[0562] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1-isopropyl-1H-pyrazole-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridine-6-yl)methanone (7);

[0563] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (8);

[0564] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (9);

[0565] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (10);

[0566] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(difluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (11);

[0567] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(difluoromethoxy)-3-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (12);

[0568] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methoxyazetidine-1-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (13);

[0569] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (14);

[0570] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (15);

[0571] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (16);

[0572] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)-methanone (17);

[0573] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1-isopropyl-1H-pyrazole-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridin-6-yl)methanone (18);

[0574] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (19);

[0575] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (20);

[0576] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (21);

[0577] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (22);

[0578] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (23);

[0579] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (24);

[0580] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (25);

[0581] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(difluoromethoxy)phenyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (26);

[0582] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (27);

[0583] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (28);

[0584] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (29);

[0585] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (30);

[0586] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (31);

[0587] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (32);

[0588] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-(methoxymethyl)-azetidine-1-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (33);

[0589] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (34);

[0590] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (35);

[0591] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(((R)-2-fluoro-3-hydroxy-3-methylbutyl)amino)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (36);

[0592] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-3-(hydroxymethyl)azetidine-1-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (37);

[0593] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (38);

[0594] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (39);

[0595] 3((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (40);

[0596] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (41);

[0597] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (42);

[0598] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (43);

[0599] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(difluoromethoxy)-3-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (44);

[0600] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(5-fluoro-2-methoxypyridine-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (45);

[0601] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (46);

[0602] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(difluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (47);

[0603] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (48);

[0604] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (49);

[0605] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methoxyazetidine-1-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (50);

[0606] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-((R)-3-hydroxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (51);

[0607] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (52);

[0608] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (53);

[0609] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (54);

[0610] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (55);

[0611] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide (56);

[0612] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (57);

[0613] N-(7-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-4-chloro-1-methyl-1H-indazole-3-yl)methanesulfonamide (58);

[0614] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (59);

[0615] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (60);

[0616] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (61);

[0617] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (62);

[0618] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (63);

[0619] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (64);

[0620] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (65);

[0621] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (66);

[0622] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (67);

[0623] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (68);

[0624] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide (69);

[0625] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (70);

[0626] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (71);

[0627] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(5-fluoro-2-methoxypyridine-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (72);

[0628] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(difluoromethoxy)-3-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (73);

[0629] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (74);

[0630] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (75);

[0631] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (76);

[0632] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-hydroxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (77);

[0633] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-((R)-3-hydroxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (78);

[0634] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methoxyazetidine-1-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (79);

[0635] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (80);

[0636] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (81);

[0637] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (82);

[0638] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (83);

[0639] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide (84);

[0640] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide (85);

[0641] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (86);

[0642] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (87);

[0643] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-hydroxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (88);

[0644] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (89);

[0645] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (90);

[0646] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-3-(hydroxymethyl)azetidine-1-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (91);

[0647] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (92);

[0648] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-fluorobenzamide (93);

[0649] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (94);

[0650] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (95);

[0651] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (96);

[0652] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (97);

[0653] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (98);

[0654] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1,1-trifluoro-2-hydroxypropane-2-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (99);

[0655] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (100);

[0656] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1,1,1-trifluoro-2-hydroxypropane-2-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (101);

[0657] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (102);

[0658] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1,1,1-trifluoro-2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (103);

[0659] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (104);

[0660] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (105);

[0661] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1,1-trifluoro-2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (106, 107 as diastereomer);

[0662] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyrimidine-6-yl)methanone (108);

[0663] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyrimidine-6-yl)methanone (109);

[0664] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyrimidine-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)isoindolin-1-one (110);

[0665] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyrimidine-6-yl)methanone (111);

[0666] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyrimidine-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)-2-fluorobenzamide (112);

[0667] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyrazine-6-yl)methanone (113);

[0668] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyrazine-6-yl)methanone (114);

[0669] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyrazine-6-yl)methanone (115);

[0670] (2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyrazine-6-yl)(2,6-diazaspiro[3.3]heptane-2-yl)methanone (116);

[0671] (R)-N-(3-amino-2-fluoropropyl)-2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyrazine-6-carboxamide (117);

[0672] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (118);

[0673] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (119);

[0674] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (120);

[0675] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (121);

[0676] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (122);

[0677] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (123);

[0678] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-fluorobenzamide (124);

[0679] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide (125);

[0680] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (126);

[0681] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (127);

[0682] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-2-methylphenyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (128);

[0683] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-methoxypyridine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (129);

[0684] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-(4-aminopiperidine-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (130);

[0685] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (131);

[0686] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo-[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)isoindolin-1-one (132);

[0687] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)-2-fluorobenzamide (133);

[0688] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (134);

[0689] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)isoindolin-1-one (135);

[0690] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (136);

[0691] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (137);

[0692] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (138);

[0693] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (139);

[0694] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (140);

[0695] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide (141);

[0696] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone (142);

[0697] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (143);

[0698] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylbenzo[b]thiophene-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (144);

[0699] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (145);

[0700] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (146);

[0701] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (147);

[0702] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (148);

[0703] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (149);

[0704] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]-heptane-2-carbonyl)-4-methoxy-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (150);

[0705] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (151);

[0706] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-fluorobenzamide (152);

[0707] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide (153);

[0708] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (154);

[0709] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (155);

[0710] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (156);

[0711] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (157);

[0712] 3-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-ethoxypiperidin-1-yl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (158);

[0713] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (159);

[0714] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-(4-aminopiperidine-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (160);

[0715] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (161);

[0716] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide (162);

[0717] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (163);

[0718] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylbenzofuran-6-yl)methanone (164);

[0719] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylbenzofuran-6-yl)methanone (165);

[0720] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)isoindolin-1-one (166);

[0721] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylbenzofuran-6-yl)methanonecyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (167);

[0722] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)isoindolin-1-one (168);

[0723] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylbenzofuran-6-yl)methanone (169);

[0724] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)-2-fluorobenzamide (170);

[0725] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylbenzofuran-6-yl)methanone (171);

[0726] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-methoxypyridine-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylbenzofuran-6-yl)methanone (172);

[0727] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methoxyazetidine-1-yl)- 1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylbenzofuran-6-yl)methanone (173);

[0728] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylbenzofuran-6-yl)methanone (174);

[0729] 6-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one (175);

[0730] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (176);

[0731] 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (177);

[0732] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (178);

[0733] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (179);

[0734] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1-isopropyl-1H-pyrazole-4-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (180);

[0735] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (181);

[0736] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (182);

[0737] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide (183);

[0738] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (184);

[0739] 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-fluorobenzamide (185);

[0740] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-methoxypyridine-4-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (186);

[0741] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (187);

[0742] 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-3-methylpicolinamide (188);

[0743] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (189);

[0744] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methoxyazetidine-1-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (190);

[0745] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-(4-aminopiperidine-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (191);

[0746] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(piperazine-1-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (192);

[0747] 1-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)piperazine-2-one (193);

[0748] ((3R,5R)-3-amino-5-fluoropiperidine-1-yl)(2-(1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (194);

[0749] 5-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one (195);

[0750] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-fluorobenzamide (196);

[0751] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (197);

[0752] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (198);

[0753] 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide (199);

[0754] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (200);

[0755] ((3R,5R)-3-amino-5-fluoropiperidine-1-yl)(2-(1-(cyclopropylmethyl)-6-(piperazine-1-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (201);

[0756] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(4-aminopiperidin-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (202);

[0757] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone (203);

[0758] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone (204);

[0759] 1-[2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one (205);

[0760] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzamide (206);

[0761] 4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide (207);

[0762] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide (208);

[0763] [2-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (209);

[0764] [3-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (210);

[0765] N-{[3-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}methanesulfonamide (211);

[0766] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(3-methoxyphenyl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (212);

[0767] N-[3-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanesulfonamide (213);

[0768] N-[4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]acetamide (214);

[0769] N-{[3-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}acetamide (215);

[0770] N-[4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanesulfonamide (216);

[0771] 4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-N,N-dimethylbenzamide (217);

[0772] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (218);

[0773] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-indazole-5-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (219);

[0774] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[3-(2H-1,2,3,4-tetrazole-5-yl)phenyl]-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (220);

[0775] N-{[4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}acetamide (221);

[0776] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-4-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (222);

[0777] 2-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)benzamide (223);

[0778] N-{[4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}methanesulfonamide (224);

[0779] 6-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-8-fluoro-5-methyl-1,2-dihydroquinoline-2-one (225);

[0780] N-[5-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)pyridin-2-yl]acetamide (226);

[0781] [3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (227);

[0782] N-{[4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}acetamide (228);

[0783] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)benzamide (229);

[0784] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-N,N-dimethylbenzamide (230);

[0785] N-[4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanesulfonamide (231);

[0786] N-{[3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}acetamide (232);

[0787] [2-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (233);

[0788] N-{[4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}methanesulfonamide (234);

[0789] N-{[3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl} methanesulfonamide (235);

[0790] [3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (236);

[0791] 2-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)benzamide (237);

[0792] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-4-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}piperidine-3-amine (238);

[0793] 6-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-8-fluoro-5-methyl-1,2-dihydroquinoline-2-one (239);

[0794] N-[5-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)pyridin-2-yl]acetamide (240);

[0795] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidin-3-amine (241);

[0796] 1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-N,N-dimethylpiperidin-4-carboxamide (242);

[0797] N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylacetamide (243);

[0798] N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylacetamide (244);

[0799] methyl N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylcarbamate (245);

[0800] N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylmethanesulfonamide (246);

[0801] N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)azetidine-3-yl]-N-methylmethanesulfonamide (247);

[0802] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}piperidin-3-amine (248);

[0803] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}piperidin-3-amine (249);

[0804] 2-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N,N-dimethylacetamide (250);

[0805] (3R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(3-methoxyazetidine-1-carbonyl)piperidin-1-yl]-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}piperidin-3-amine (251);

[0806] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylacetamide (252);

[0807] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylacetamide (253);

[0808] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylmethanesulfonamide (254);

[0809] methyl N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylcarbamate (255);

[0810] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)azetidine-3-yl]-N-methylmethanesulfonamide (256);

[0811] 1-[2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one (257);

[0812] 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one (258);

[0813] 3-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol (259);

[0814] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide (260);

[0815] 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one (261);

[0816] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzamide (262);

[0817] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide (263);

[0818] 5-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylpyridin-2-carboxamide (264);

[0819] ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-((R)-3-hydroxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (265);

[0820] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(morpholine-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (266);

[0821] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)morpholine-3-one (267);

[0822] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (268);

[0823] 8-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one (269);

[0824] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidin-3-amine (270);

[0825] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl]-N-methylacetamide (271);

[0826] methyl N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl]-N-methylcarbamate (272);

[0827] 1-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl]pyrrolidin-2-one (273);

[0828] (5S)-5-{[(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)oxy]methyl}pyrrolidin-2-one (274);

[0829] 4-{[(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)oxy]methyl}pyrrolidin-2-one (275);

[0830] (3R)-1-{4-chloro-2-[1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidin-3-amine (276);

[0831] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide (277);

[0832] 3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol (278);

[0833] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide (279);

[0834] 1-[4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one (280);

[0835] 1-[2-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one (281);

[0836] 3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol (282);

[0837] 3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol (283);

[0838] 5-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindole-1-one (284);

[0839] 6-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindole-1-one (285);

[0840] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzamide (286);

[0841] 5-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylpyridin-2-carboxamide (287);

[0842] (3R)-1-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidine-3-amine (288);

[0843] (3R,5R)-1-{4-chloro-2-[6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidine-3-amine (289);

[0844] (3R,5R)-1-{4-chloro-2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidine-3-amine (290);

[0845] (3R)-1-{4-chloro-2-[6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidine-3-amine (291);

[0846] (3R)-1-{4-chloro-2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidine-3-amine (292);

[0847] 5-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-2,3-dihydro-1H-isoindole-1-one (293);

[0848] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-3-chlorobenzamide (294);

[0849] (7R)-2-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-indole-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (295);

[0850] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methoxyazetidine-1-yl)-1H-indole-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (296);

[0851] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-1H-indazole-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (297);

[0852] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (298);

[0853] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (299);

[0854] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (300);

[0855] 3-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol (301);

[0856] 1-[2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one (302);

[0857] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxybenzamide (303);

[0858] 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one (304);

[0859] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide (305);

[0860] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(7-fluoro-1H-indazole-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (306);

[0861] 5-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylpyridin-2-carboxamide (307);

[0862] methyl N-[5-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate (308);

[0863] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidine-3-amine (309);

[0864] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidine-3-amine (310);

[0865] (3R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidine-3-amine (311);

[0866] 6-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-5-methyl-1,2-dihydroquinoline-2-one (312);

[0867] 3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol (313);

[0868] 3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol (314);

[0869] 6-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindole-1-one (315);

[0870] 4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzamide (316);

[0871] 5-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindole-1-one (317);

[0872] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(morpholine-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (318);

[0873] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)morpholine-3-one (319);

[0874] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (320);

[0875] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidine-3-amine (321);

[0876] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidine-3-amine (322);

[0877] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidine-3-amine (323);

[0878] 6-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-5-methyl-1,2-dihydroquinoline-2-one (324);

[0879] methyl N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl]-N-methylcarbamate (325);

[0880] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(7-fluoro-1H-indazole-4-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (326);

[0881] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-1H-indazole-4-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (327);

[0882] 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]imidazolidin-2-one (328);

[0883] 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]pyrrolidin-2-one (329);

[0884] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(7-fluoro-1H-indazole-6-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (330);

[0885] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-5-fluoro-2-methylbenzamide (331);

[0886] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-6-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (332);

[0887] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (333);

[0888] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-methylbenzamide (334);

[0889] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-3-(trifluoromethyl)benzamide (335);

[0890] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(7-fluoro-1H-indazole-6-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (336);

[0891] N-[7-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-4-chloro-1-methyl-1H-indazole-3-yl]methanesulfonamide (337);

[0892] 1-[2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]imidazolidin-2-one (338);

[0893] 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide (339);

[0894] 5-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-N-methylpyridine-2-carboxamide (340);

[0895] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrazole-4-yl)-1H-indole-2-yl]-3-methylpyrazole[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (341);

[0896] N-{[4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}methanesulfonamide (342);

[0897] N-{[3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}acetamide (343);

[0898] [3-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (344);

[0899] (3R)-1-{2-[1'-(cyclopropylmethyl)-1H,1'H-[5,6'-biindole]-2'-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}piperidine-3-amine (345);

[0900] 6-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-8-fluoro-5-methyl-1,2-dihydroquinoline-2-one (346);

[0901] N-[4-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanesulfonamide (347);

[0902] N-[5-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)pyridin-2-yl]acetamide (348);

[0903] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (349);

[0904] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(morpholine-4-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (350);

[0905] (7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine (351);

[0906] methyl N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylcarbamate (352);

[0907] N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylacetamide (353);

[0908] N-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylmethanesulfonamide (354);

[0909] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(pyrrolidin-1-carbonyl)piperidin-1-yl]-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidin-3-amine (355);

[0910] 1-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]pyrrolidin-2-one (356);

[0911] 3-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-1,3-oxazolidin-2-one (357);

[0912] methyl N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylcarbamate (358);

[0913] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylacetamide (359);

[0914] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylmethanesulfonamide (360);

[0915] (3R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(pyrrolidin-1-carbonyl)piperidin-1-yl]-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}piperidin-3-amine (361);

[0916] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-N-methylmethanesulfonamide (362);

[0917] 1-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]pyrrolidin-2-one (363);

[0918] 3-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-1,3-oxazolidin-2-one (364);

[0919] (3R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(1H-pyrazole-1-yl)piperidin-1-yl]-1H-indole-2-yl]-3-methylpyrazole[1,5-a]pyridin-6-carbonyl}piperidin-3-amine (365);

[0920] N-[1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)azetidine-3-yl]-N-methylmethanesulfonamide (366);

[0921] N-{[3-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}methanesulfonamide (367);

[0922] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[3-(2H-1,2,3,4-tetrazole-5-yl)phenyl]-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (368);

[0923] N-[4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanesulfonamide (369);

[0924] N-{[4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methyl}methanesulfonamide (370);

[0925] [3-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]methanol (371);

[0926] 2-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)benzamide (372);

[0927] 4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)benzamide (373);

[0928] (3R,5R)-1-{2-[1'-(cyclopropylmethyl)-1H,1'H-[5,6'-biindole]-2'-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-5-fluoropiperidine-3-amine (374);

[0929] [4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chloro-5-fluorophenyl]methanol (375);

[0930] 6-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-8-fluoro-5-methyl-1,2-dihydroquinoline-2-one (376);

[0931] 4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-3-chlorobenzamide (377);

[0932] 4-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-methylbenzamide (378);

[0933] (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidine-3-amine (379);

[0934] 2-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)propan-2-ol (homochiral) (380);

[0935] 2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1-difluoropropan-2-ol (mixture of diastereoisomers) (381);

[0936] 2-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1,1-trifluoropropan-2-ol (mixture of diastereoisomers) (382);

[0937] 2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1,1-trifluoropropan-2-ol (383);

[0938] 1-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-cyclopropylethanol-1-ol (384);

[0939] 1-(2-{6-[(3R)-3-aminopiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)ethanol-1-ol (mixture of diastereoisomers) (385);

[0940] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (386);

[0941] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (387);

[0942] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (388);

[0943] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (389);

[0944] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (390);

[0945] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (391);

[0946] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (392);

[0947] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (393);

[0948] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (394);

[0949] (R)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (395);

[0950] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (396);

[0951] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (397);

[0952] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (398);

[0953] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (399);

[0954] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (400);

[0955] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (401);

[0956] (R)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (402);

[0957] (S)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (403);

[0958] (S)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (404);

[0959] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (405);

[0960] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (406);

[0961] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (407);

[0962] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (408);

[0963] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (409);

[0964] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethan-1-one (410);

[0965] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (411);

[0966] 1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (412);

[0967] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethan-1-one (413);

[0968] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (414);

[0969] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (415);

[0970] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (416);

[0971] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxy-2-methylpropan-1-one (417);

[0972] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxy-2-methylpropan-1-one (418);

[0973] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (419);

[0974] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (420);

[0975] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (421);

[0976] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (422);

[0977] (S)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (423);

[0978] (S)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (424);

[0979] (R)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (425);

[0980] (R)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (426);

[0981] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (427);

[0982] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (428);

[0983] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (429);

[0984] Ethyl 2-(7-(1-(tert-butoxycarbonyl)piperidine-4-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-carboxylate (430);

[0985] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-3-hydroxypropan-1-one (430);

[0986] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-isopropoxyethane-1-one (431);

[0987] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-isopropoxyethane-1-one (432);

[0988] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-3-hydroxy-2,2-dimethylpropan-1-one (433);

[0989] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-3-hydroxy-2,2-dimethylpropan-1-one (434);

[0990] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxy-2-methylpropan-1-one (435);

[0991] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxy-2-methylpropan-1-one (436);

[0992] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-3-hydroxypropan-1-one (437);

[0993] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxyethane-1-one (438);

[0994] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxyethane-1-one (439);

[0995] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1R,3S)-3-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (440);

[0996] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-ethoxyethane-1-one (441);

[0997] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-ethoxyethane-1-one (442);

[0998] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (443);

[0999] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (444);

[1000] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-3-methylbutan-1-one (445);

[1001] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-3-methylbutan-1-one (446);

[1002] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1S,3R)-3-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (447);

[1003] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1S,3R)-3-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (448);

[1004] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1R,3S)-3-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (449);

[1005] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (450);

[1006] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (451);

[1007] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (452);

[1008] 1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)-2-methoxyethane-1-one (453);

[1009] (S)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (454);

[1010] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (455);

[1011] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (456);

[1012] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (457);

[1013] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (458);

[1014] (S)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (459);

[1015] (R)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (460);

[1016] (R)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (461);

[1017] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (462);

[1018] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (463);

[1019] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(thiophene-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (464);

[1020] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (465);

[1021] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (466);

[1022] (4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)(3-hydroxycyclobutyl)methanone (467);

[1023] methyl (R)-4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-carboxylate (468);

[1024] methyl 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-carboxylate (469);

[1025] methyl 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-carboxylate (470);

[1026] (R)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxypropan-1-one (471);

[1027] (R)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxypropan-1-one (472);

[1028] (2R)-1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)-2-hydroxypropan-1-one (473);

[1029] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(thiophene-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (474);

[1030] (4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)(thiophene-2-yl)methanone (475);

[1031] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (476);

[1032] 1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (477);

[1033] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (478);

[1034] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethan-1-one (479);

[1035] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (480);

[1036] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (481);

[1037] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (482);

[1038] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)ethan-1-one (483);

[1039] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (484);

[1040] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (485);

[1041] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (486);

[1042] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (487);

[1043] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydrofuran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (488);

[1044] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydrofuran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (489);

[1045] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (490);

[1046] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (491);

[1047] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (492);

[1048] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxy-2-methylpropan-1-one (493);

[1049] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-3-methylbutan-1-one (494);

[1050] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-3-methylbutan-1-one (495);

[1051] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (496);

[1052] (R)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (497);

[1053] (R)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (498);

[1054] (S)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (499);

[1055] (S)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one (500);

[1056] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxy-2-methylpropan-1-one (501);

[1057] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (502);

[1058] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (503);

[1059] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (504);

[1060] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (505);

[1061] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)ethan-1-one (506);

[1062] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)ethane-1-one (507);

[1063] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (508);

[1064] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (509);

[1065] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (510);

[1066] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (511);

[1067] (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)piperidin-1-yl)-2-methoxyethanol-1-one (512);

[1068] 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)piperidin-1-yl)-2-methoxyethane-1-one (513);

[1069] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (514);

[1070] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (515);

[1071] (R)-1-(3-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxy-2-methylpropan-1-one (516);

[1072] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (517);

[1073] 1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxy-2-methylpropan-1-one (518);

[1074] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (519);

[1075] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (520);

[1076] (R)-1-(3-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)ethan-1-one (521);

[1077] 1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)ethane-1-one (522);

[1078] (S)-1-(3-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (523);

[1079] (S)-1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (524);

[1080] (R)-1-(3-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (525);

[1081] (R)-1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (526);

[1082] 1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxyethane-1-one (527);

[1083] (R)-1-(3-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxyethane-1-one (528);

[1084] (R)-1-(3-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxyethane-1-one (529);

[1085] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (530);

[1086] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1R,3S)-3-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (531);

[1087] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1R,3S)-3-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (532);

[1088] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1S,3R)-3-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (533);

[1089] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1S,3R)-3-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (534);

[1090] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (535);

[1091] (R)-1-(3-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxy-2-methylpropan-1-one (536);

[1092] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (537);

[1093] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (538);

[1094] ((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (539);

[1095] (R)-1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (540);

[1096] (R)-1-(3-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (541);

[1097] (S)-1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (542);

[1098] (S)-1-(3-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)-2-methoxypropan-1-one (543);

[1099] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (544);

[1100] ((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (545);

[1101] (R)-1-(3-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxyethanol-1-one (546);

[1102] 1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxyethane-1-one (547);

[1103] 1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidin-1-yl)ethane-1-one (548);

[1104] 1-(3-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)ethane-1-one (549);

[1105] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (550);

[1106] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (551);

[1107] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (552);

[1108] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (553);

[1109] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (554);

[1110] (R)-(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)(3-aminopiperidine-1-yl)methanone (555);

[1111] (2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (556);

[1112] (2-(7-(2-(4-amino-1H-pyrazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (557);

[1113] (R)-(2-(7-(2-(4-amino-1H-pyrazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridine-6-yl)(3-aminopiperidine-1-yl)methanone (558);

[1114] (S)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (559);

[1115] (S)-5-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (560);

[1116] (R)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (561);

[1117] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (562);

[1118] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (563);

[1119] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (564);

[1120] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (565);

[1121] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (566);

[1122] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (567);

[1123] (S)-5-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (568);

[1124] (S)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (569);

[1125] (R)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (570);

[1126] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (571);

[1127] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (572);

[1128] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (573);

[1129] (2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (574);

[1130] (R)-(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)(3-aminopiperidine-1-yl)methanone (575);

[1131] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (576);

[1132] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (577);

[1133] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (578);

[1134] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)-1-methylpyrrolidin-2-one (579);

[1135] (R)-(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)(3-aminopiperidine-1-yl)methanone (580);

[1136] (2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (581);

[1137] (R)-(2-(7-(2-(4-amino-1H-pyrazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazole[1,5-a]pyridine-6-yl)(3-aminopiperidine-1-yl)methanone (582);

[1138] (2-(7-(2-(4-amino-1H-pyrazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazole[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (583);

[1139] (S)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (584);

[1140] (S)-5-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (585);

[1141] (R)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (586);

[1142] (R)-5-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (587);

[1143] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (588);

[1144] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (589);

[1145] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one (590);

[1146] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (591);

[1147] (2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (592);

[1148] (R)-(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidine-1-yl)methanone (593);

[1149] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(2-(2-methyl-1H-imidazole-1-yl)ethoxy)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (594);

[1150] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(2-(2-methyl-1H-imidazole-1-yl)ethoxy)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (595);

[1151] (R)-(3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(oxetane-3-ylmethoxy)-1H-pyrrolo[2,3-c]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone (596);

[1152] (2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (597);

[1153] (R)-(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidine-1-yl)methanone (598);

[1154] (R)-(2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidine-1-yl)methanone (599);

[1155] (2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridine-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (600);

[1156] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (601);

[1157] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (602);

[1158] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (603);

[1159] (5R)-5-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (604);

[1160] 4-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (605);

[1161] 4-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (606);

[1162] (5R)-5-(((2-(6-((7S)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (607);

[1163] 4-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (608);

[1164] (R)-(2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidine-1-yl)methanone (609);

[1165] (2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (610);

[1166] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(2-(2-methyl-1H-imidazole-1-yl)ethoxy)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (611);

[1167] (R)-(3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(2-(2-methyl-1H-imidazole-1-yl)ethoxy)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone (612);

[1168] (2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (613);

[1169] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (614);

[1170] 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (615);

[1171] (2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (616);

[1172] (R)-(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidine-1-yl)methanone (617);

[1173] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (618);

[1174] 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one (619);

[1175] (2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl)methanone (620); and

[1176] ((3R,5R)-3-amino-5-fluoropiperidin-1-yl) (2-(3-(cyclopropylmethyl)-4-(1-(2-hydroxyethyl)-1H-pyrazole-4-yl)benzo[b]thiophene-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridine-6-yl)methanone (621);

[1177] or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.

[1178] In one embodiment, the present invention uses the RFMS PAD4 functional verification disclosed herein to IC 50 Value ≤ 4.000 μM, preferably IC 50 Value ≤ 1.000 μM, preferably IC 50 Value ≤ 0.500 μM, preferably IC 50 Value ≤ 0.100 μM, more preferably IC 50 Value ≤ 0.050 μM, more preferably IC 50 Value ≤ 0.03 μM, more preferably IC 50 Value ≤ 0.02 μM, more preferably IC 50 Provides a compound having a value ≤ 0.01 μM.

[1179] As defined above and described herein, X2 is selected from N and CR4. In some embodiments, X2 is N. In some embodiments, X2 is CR4. In certain embodiments, X2 is selected from the functional groups shown in the following examples.

[1180] As defined above, R1 is

[1181]

[1182] Selected from.

[1183] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is

[1184]

[1185] is. In some embodiments, R1 is

[1186]

[1187] It is selected from. In some embodiments, R1 is

[1188]

[1189] It is selected from. In some embodiments, R1 is

[1190]

[1191] It is selected from. In some embodiments, R1 is

[1192]

[1193] Selected from.

[1194] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is am.

[1195] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is am.

[1196] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is am.

[1197] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is am.

[1198] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is am.

[1199] In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In some embodiments, R1 is is. In certain embodiments, R1 is selected from the functional groups shown in the following examples. R1 is preferably

[1200]

[1201] Selected from.

[1202] As defined above and described herein, R2 is H, F, Cl, Br, -OR b , and one or more R e C arbitrarily substituted as 1-3 It is selected from alkyls. In some embodiments, R2 is H. In some embodiments, R2 is F, Cl, or Br. In some embodiments, R2 is F, and in some embodiments, R2 is C 1-3 It is alkyl. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl. In some embodiments, R2 is propyl. In some embodiments, R2 is OR bis. In some embodiments, R2 is -OCH3. In some embodiments, R2 is -OCH2CH3. In some embodiments, R2 is -OCH2CH2CH3. In certain embodiments, R2 is -OCH(F)2. In certain embodiments, R2 is selected from the functional groups shown in the following examples. R2 is preferably selected from H, F, Cl, CH3, and OCH3.

[1203] As defined above and described herein, R3 is selected from CH3 and CD3. In some embodiments, R3 is CH3. In some embodiments, R3 is CD3. In certain embodiments, R3 is selected from the functional groups shown in the following examples. R3 is preferably selected from H, F, Cl, CH3, and CH2OH.

[1204] As defined above and described herein, R4 is H, F, Cl, Br, C 1-4 alkyl, OC substituted with one or more R5s 1-4 alkyl,

[1205]

[1206]

[1207] Selected from.

[1208] In some embodiments, R4 is H. In some embodiments, R4 is selected from F, Cl, and Br.

[1209] In some embodiments, R4 is C 1-3 It is an alkyl. In some embodiments, R4 is CH3.

[1210] In some embodiments, R4 is

[1211]

[1212] Selected from.

[1213] In some embodiments, R4 is is. In some embodiments, R4 is is. In some embodiments, R4 is is. In some embodiments, R4 is am.

[1214] In some embodiments, R4 is is. In some embodiments, R4 is ..., where R5 is selected from F, Cl, -OH, -C(=O)NH2. In some embodiments, R4 is is. In some embodiments, R4 is am.

[1215] In some embodiments, R4 is

[1216]

[1217] It is selected from. In some embodiments, R4 is is. In some embodiments, R4 is is. In some embodiments, R4 is am.

[1218] In some embodiments, R4 is It is selected from. In some embodiments, R4 is am.

[1219] In some embodiments, R4 is It is selected from. In some embodiments, R4 is and, where R5 is selected from F, Cl, and CH2OH. In some embodiments, R4 is And, where R5 is selected from F, Cl, -OH, -OCH3, -OCH2CH3, and NH2. In certain embodiments, R4 is selected from the functional groups shown in the following examples.

[1220] R4 is optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH, either alone or together with R5 and R6. 1-5 Alkyl, C 3-6 cycloalkyl,

[1221]

[1222]

[1223]

[1224]

[1225] Selected from.

[1226] As defined above and described herein, R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkinyl, -(CR d R d ) r OR b , -(CR d R d ) r S(O) p R c , -(CR d R d ) r S(O) p NR a R a , -(CR d R d ) r NR a S(O) p R c , -(CR d R d ) r NR a R a , -(CR d R d ) r NR a C(=O)R b , -(CR d R d ) r NR a C(=O)OR b , -(CR d R d ) r NR a C(=O)NRa R a , -(CR d R d ) r C(=O)R b , -(CR d R d ) r C(=O)OR b , -(CR d R d ) r C(=O)NR a R a , -(CR d R d ) r OC(=O)R b , -(CR d R d ) r OC(=O)OR b , -(CR d R d ) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e It is selected from heterocyclils that have been arbitrarily substituted.

[1227] In some embodiments, R5 is H, F, Cl, CN, C 1-4 Alkyl (optionally substituted with OH, NH2, and COOH), SC 1-4 Alkyl, S(O)2C 1-4 Alkyl, S(O)2NH-cyclopropyl, -(CH2) 0-1 NHS(O)2C 1-4 Alkyl, -NR a S(O)2C 2-4 Alkenyl, -(CH2) 0-1 OH, OC 1-4 Alkyl, -(CH2) 0-1 NH2, -(CH2) 0-1 NHC(=O)C 1-4 Alkyl, -NR a C(=O)C 2-4Alkenyl, -NHC(=O)C 2-4 alkynyl, -(CH2) 0-1 C(=O)OH, -C(=O)OC 1-4 Alkyl, -NHC(=O)OC 1-4 Alkyl, -NHC(=O)O(CH2)2OC 1-4 Alkyl, -NHC(=O)OCH2-cyclopropyl, -NHC(=O)NH2, C(=O)NHC 1-4 Alkyl, CONH(CH2) 1-2 C(=O)OH, -(CH2) 0-1 C(=O)NH2, -(CH2) 0-1 C(=O)NHC 1-4 Alkyl, C(=O)NH-pyridine, -C(=O)NH(CH2)2N(C 1-4 Alkyl)2, -C(=O)NH(CH2)2OH, -C(=O)NH(CH2)2S(O)2C 1-4 Alkyl, and -OC(=O)C 1-4 Selected from alkyls.

[1228] In some embodiments, R5 is F. In some embodiments, R5 is C 1-4 It is an alkyl. In some embodiments, R5 is -OH or -OC 1-3 It is an alkyl. In some embodiments, R5 is -NHS(O)2C 1-4 It is an alkyl. In certain embodiments, R5 is selected from the functional groups shown in the following examples.

[1229] In some embodiments, R4 is an OC substituted with one or more R5s. 1-3 It is alkyl; and R5 is

[1230]

[1231] am.

[1232] As defined above and described herein, R6 is H, and one or more R e C arbitrarily substituted as 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -(CH2) r -C(=O)NRa R a , -C(=O) (CH2) r NR a C(=O)R b , -C(=O)OR b , -S(O) p NR a R a , one or more R e An aryl aryl arbitrarily substituted with , or one or more R e It is selected from heterocyclils optionally substituted with . In some embodiments, R6 is H. In some embodiments, R6 is methyl or isopropyl. In some embodiments, R6 is -(CH2)2OH. In certain embodiments, R6 is selected from the functional groups shown in the following examples. R6 is preferably H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e It is selected from heterocyclils optionally substituted with . In some embodiments, R4, R5, and R6 together

[1233]

[1234] Selected from.

[1235] As defined above and described herein, R7 is H, F, Cl, Br, and C 1-4 It is selected from alkyls. In some embodiments, R7 is H. In some embodiments, R7 is C 1-3It is an alkyl. In certain embodiments, R7 is selected from the functional groups shown in the following examples. R7 is preferably selected from H, F, and Cl.

[1236] As defined above and described herein, R8 is H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-3 It is selected from alkyls. In some embodiments, R8 is hydrogen. In some embodiments, R8 is C 3-6 C substituted with a cycloalkyl group 1-2 It is an alkyl. In some embodiments, R8 is methyl. In some embodiments, R8 is ethyl. In some embodiments, R8 is cyclopropyl. Preferably, R8 is -CH2-cyclopropyl or -CH2-cyclobutyl. In some embodiments, R8 is -CH2-cyclobutyl optionally substituted with methyl and -OH. In certain embodiments, R8 is selected from the functional groups shown in the following examples.

[1237] As defined above and described herein, R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e It forms a heterocyclic ring arbitrarily substituted with.

[1238] As defined above and described herein, R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils

[1239] As defined above and described herein, R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils

[1240] As defined above and described herein, R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls.

[1241] As defined above and described herein, R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r - Selected from heterocyclils

[1242] As defined above and described herein, R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 It is selected from cycloalkyl and phenyl.

[1243] As defined above and described herein, p is independently selected from 0, 1, and 2 in each case.

[1244] As defined above and described herein, r is 0-4. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4.

[1245] In some embodiments, the compound of formula (Ia) is selected from the examples illustrated below. In certain embodiments, the present invention provides any of the compounds described above and herein, or any pharmaceutically acceptable salts or compositions thereof, for use in therapy. In some embodiments, the present invention provides any of the compounds described above and herein in an isolated form. In some embodiments, the present invention provides a compound according to any one of the claims set forth below.

[1246] 3. Pharmaceutical composition

[1247] According to another aspect, the present invention provides a composition comprising the compound of the present invention or its stereoisomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and pharmaceutically acceptable carriers, ajuvants, or vehicles. The amount of the compound in the composition of the present invention is effective to a measureably inhibit PAD4 in a biological sample or patient. In certain embodiments, the amount of the compound in the composition of the present invention is effective to a measureably inhibit PAD4 in a biological sample or patient. In certain embodiments, the composition of the present invention is formulated for administration to a patient who requires such composition. In some embodiments, the composition of the present invention is formulated for oral administration to a patient.

[1248] As used herein, the term “subject” is used interchangeably with the term “patient” and means an animal, preferably a mammal. In some embodiments, the subject or patient is a human. In other embodiments, the subject (or patient) is a veterinary subject (or patient). In some embodiments, the veterinary subject (or patient) is a dog, cat, or horse subject.

[1249] The term "pharmaceutical acceptable carrier, ajuvant or vehicle" refers to a non-toxic carrier, ajuvant or vehicle that does not impair the pharmacological activity of the compound formulated with it. Pharmaceutically acceptable carriers, ajuvants, or vehicles that may be used in the composition of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffering materials such as phosphate, glycine, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based materials, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fats.

[1250] The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or through an implanted reservoir. As used herein, the term "parenterally" includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously. The sterile injectable form of the compositions of the present invention may be an aqueous or oil suspension. These suspensions may be formulated according to techniques known in the relevant art using suitable dispersants or wetting agents and suspending agents. The sterile injectable formulation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, such as, for example, a solution in 1,3-butanediol. Among the permissible vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixative oils are commonly used as solvents or suspension media.

[1251] For this purpose, any non-irritating fixing oil, including synthetic mono- or di-glycerides, may be used. Fatty acids, such as oleic acid and its glyceride derivatives, are useful for the preparation of injectables, and in particular, natural pharmaceutically acceptable oils, such as olive oil or castor oil, in their polyoxyethylated forms, are useful. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose, or similar dispersants commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span, and other emulsifiers, or bioavailability enhancers commonly used in the preparation of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for formulation purposes.

[1252] Pharmaceutically acceptable compositions of the present invention may be administered orally in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricants, such as magnesium stearate, are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. If an aqueous suspension is required for oral use, the active ingredient is combined with an emulsifier and a suspending agent. If desired, certain sweeteners, flavorings, or colorings may also be added.

[1253] Alternatively, pharmaceutically acceptable compositions of the present invention may be administered in the form of suppositories for rectal administration. These may be prepared by mixing an agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and thus melts rectally to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[1254] The pharmaceutically acceptable compositions of the present invention may also be administered topically, particularly when the therapeutic target, including diseases of the eyes, skin, or lower gastrointestinal tract, comprises a site or organ that is easily accessible by topical application. Topical formulations suitable for each of these areas or organs are readily prepared.

[1255] Topical application to the lower intestine may be performed with rectal suppository preparations (see above) or suitable enema preparations. Topical-transdermal patches may also be used.

[1256] For topical application, the provided pharmaceutically acceptable composition may be formulated into a suitable ointment containing an active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes, and water. Alternatively, the provided pharmaceutically acceptable composition may be formulated into a suitable lotion or cream containing an active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[1257] For ophthalmic use, the provided pharmaceutically acceptable composition may be formulated as a micro-suspension in isotonic pH-adjusted sterile saline, with or without a preservative such as benzyl alcoholnium chloride, or preferably as a solution in isotonic pH-adjusted sterile saline. Alternatively, for ophthalmic use, the pharmaceutically acceptable composition may be formulated as an ointment, for example, in petrolatum.

[1258] Pharmaceutically acceptable compositions of the present invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques widely known in the field of pharmaceutical formulation technology and may be prepared as a solution in saline using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizers or dispersants.

[1259] Preferably, the pharmaceutically acceptable composition of the present invention is formulated for oral administration. Such formulation may be administered with or without food. In some embodiments, the pharmaceutically acceptable composition of the present invention is administered without food. In other embodiments, the pharmaceutically acceptable composition of the present invention is administered with food.

[1260] Pharmaceutically acceptable compositions of the present invention may be administered to humans and other animals as needed orally, rectally, parenterally, into a tubule, vaginally, intraperitoneally, topically (as a powder, ointment, or drop), buccally, or as an oral or nasal spray, etc. In certain embodiments, compounds of the present invention may be administered orally or parenterally at least once a day at a dosage level of about 0.01 mg / kg to about 50 mg / kg and preferably about 1 mg / kg to about 25 mg / kg based on the subject's body weight per day to obtain the desired therapeutic effect.

[1261] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the relevant art, such as, for example, water or other solvents; solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide; oils (particularly, cottonseed, peanut, corn, germ, olive, castor, and sesame oils); fatty acid esters of glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and sorbitan, and mixtures thereof. In addition to inert diluents, the oral composition may also include ajuvants, such as humectants, emulsifiers and suspending agents, sweeteners, flavoring agents, and perfumes.

[1262] Injectable formulations, e.g., sterile injectable aqueous or oil suspensions, may be formulated according to the art known to the art using suitable dispersants or wetting agents and suspending agents. Sterile injectable formulations may also be sterile injectable solutions, suspensions, or emulsions in diluents or solvents acceptable for non-toxic parenteral administration, e.g., solutions in 1,3-butanediol. In particular, acceptable vehicles and solvents that may be used are water, Ringer's solution, USP, and isotonic sodium chloride solutions. Additionally, sterile fixing oils are typically used as solvents or suspension media. For this purpose, any non-irritating fixing oil, including synthetic mono- or diglycerides, may be used. Additionally, fatty acids, such as oleic acid, may also be used in the preparation of injectable formulations.

[1263] Injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating a sterile agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable media before use.

[1264] To prolong the effects of the compounds of the present invention, it is often desirable to slow down the absorption of the compounds from subcutaneous or intramuscular injections. This can be achieved by using liquid suspensions of crystalline or amorphous materials having poor water solubility. In this case, the absorption rate of the compound depends on its dissolution rate, which may also depend on crystal size and crystalline form. Alternatively, delayed absorption of the compound in parenterally administered forms is achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are prepared by forming a microencapsulation matrix of the compound in a biodegradable polymer, such as polylactide-polyglycolide. Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the release rate of the compound can be controlled. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydride). Injectable depot formulations are also prepared by encapsulating the compound in liposomes or microemulsions that are compatible with body tissues.

[1265] A composition for rectal or vaginal administration is preferably a suppository that can be prepared by mixing the compound of the present invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or suppository wax, which is solid at ambient temperature but liquid at body temperature, and thus melts in the rectal or vaginal cavity and releases the active compound.

[1266] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In this solid dosage form, the active compound comprises at least one inert pharmaceutically acceptable excipient or carrier, such as sodium citrate or dical phosphate and / or (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as, for example, carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; (c) humectants, such as glycerol; (d) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (e) dissolution retardants, such as paraffin; (f) absorption promoters, such as quaternary ammonium compounds; (g) wetting agents, such as, cetyl alcohol and glycerol monostearate; (h) absorbents, such as kaolin and bentonite clay; and (i) lubricants, such as talc. It is mixed with calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also include a buffer.

[1267] Similar types of solid compositions may also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose, as well as high molecular weight polyethylene glycol. Solid dosage forms such as tablets, coated tablets, capsules, pills, and granules may be manufactured using coatings and shells such as enteric coatings and other coatings widely known in the field of pharmaceutical formulation technology. These may optionally contain opacifying agents and may also be compositions that release only the active ingredient(s), or preferentially, in a specific part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be used include polymeric materials and waxes. Similar types of solid compositions may also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose, as well as high molecular weight polyethylene glycol.

[1268] The active compound may also be in a microencapsulated form using one or more excipients as mentioned above. Solid dosage forms such as tablets, coated tablets, capsules, pills, and granules may be manufactured using coatings and shells such as enteric coatings, controlled-release coatings, and other coatings widely known in the field of pharmaceutical formulation technology. In these solid dosage forms, the active compound may be mixed with at least one inert diluent such as sucrose, lactose, or starch. These dosage forms may also include additional substances other than the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose, as in conventional practice. In the case of capsules, tablets, and pills, the dosage forms may also include a buffer.

[1269] Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed with a pharmaceutically acceptable carrier under sterile conditions and, if required, any necessary preservatives or buffers. Ophthalmic formulations, ear drops, and eye drops are also considered to be included within the scope of the present invention. Additionally, the present invention considers the use of transdermal patches, which have the added advantage of providing controlled delivery of the compounds into the body. Such dosage forms may be prepared by dissolving or dispensing the compounds in a suitable medium. Absorption enhancers may also be used to increase the flow of the compounds through the skin. The rate may be controlled by providing a rate-controlling membrane or by dispersing the compounds in a polymer matrix or gel.

[1270] The amount of the compound of the present invention that can be combined with a carrier material to prepare a composition in a single-dose form will vary depending on the host being treated and the specific mode of administration. Preferably, the provided compositions should be formulated so that a dose of 0.01 to 100 mg / kg body weight / day of the inhibitor can be administered to patients receiving these compositions.

[1271] The compounds of the present invention may be administered alone or in combination with one or more other therapeutic compounds, and possible combination therapies take the form of a fixed combination, or the administration of the compounds of the present invention and one or more other therapeutic compounds alternately or independently of each other, or the administration of a fixed combination and one or more other therapeutic compounds in combination. Examples of such other therapeutic agents include corticosteroids, rolipram, calpostine, cytokine-inhibiting anti-inflammatory drugs (CSAIDs), interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, e.g., deoxyspergualin (DSG); non-steroidal anti-inflammatory drugs (NSAIDs), e.g., ibuprofen, celecoxib, and rofecoxib; steroids, e.g., prednisone or dexamethasone; antivirals, e.g., abacavir; Antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, Prograf); cytotoxic drugs such as azathioprine and cyclophosphamide; TNF-α inhibitors such as Tenidab, anti-TNF antibodies or soluble TNF receptors, and rapamycin (sirolimus or rapamune), or derivatives thereof are included. Compounds of the present invention may be administered in addition or further, particularly for tumor therapy, in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or combinations thereof. Long-term therapy is possible in the same way as adjuvant therapy in relation to other treatment strategies as described above. Other possible treatments are therapy to maintain the patient's condition after tumor regression, or even, for example, chemoprevention therapy in patients at risk.

[1272] These additional agents may be administered individually with the compound-containing composition of the present invention as part of a multiple-dose regimen. Alternatively, these agents may be part of a single-dose form mixed with the compound of the present invention as a single composition. When administered as part of a multiple-dose regimen, the two agents may be provided simultaneously, sequentially, or with a time interval between them, typically within 5 hours of each other.

[1273] As used herein, the terms “combination,” “combined,” and related terms refer to the simultaneous or sequential administration of the therapeutic agent according to the present invention. For example, a compound of the present invention may be administered simultaneously or sequentially in the form of individual unit administrations, or together in the form of a single unit administration, with another therapeutic agent. Accordingly, the present invention provides a single unit administration form comprising a compound of the present invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, ajuvant, or vehicle.

[1274] The amounts of both the compound of the present invention and additional therapeutic agents (among these compositions including additional therapeutic agents as described above) that can be combined with a carrier material to produce a single-dose form will vary depending on the host being treated and the specific mode of administration. Preferably, the composition of the present invention should be formulated so that a dose of the compound of the present invention of 0.01 to 100 mg / kg body weight / day can be administered.

[1275] In these compositions containing additional therapeutic agents, the additional therapeutic agent and the compound of the present invention may act synergistically. Therefore, the amount of the additional therapeutic agent in these compositions will be less than that required in monotherapy using only that therapeutic agent.

[1276] The amount of additional therapeutic agent present in the composition of the present invention will be less than or equal to the amount typically administered in a composition comprising the therapeutic agent as the sole active agent. Preferably, the amount of additional therapeutic agent in the composition disclosed herein will be in the range of about 50% to 100% of the amount typically present in a composition comprising the agent as the sole therapeutic active agent.

[1277] In addition, it should be understood that specific dosages and treatment regimens for any particular patient will vary depending on various factors including the activity of the specific compound used, age, body weight, overall health, gender, diet, time of administration, elimination rate, drug combinations, the judgment of the treating physician, and the severity of the specific disease or disorder being treated. The amount of the compound of the present invention in the composition will also vary depending on the specific compound in the composition.

[1278] 4. Uses of Compounds

[1279] The compounds and compositions described herein are generally useful for inhibiting PAD4.

[1280] The activity of the compound used as an inhibitor of PAD4 in the present invention can be tested in vitro, in vivo, or in cell lines. In vitro testing includes testing to determine inhibition of PAD4. Detailed conditions for testing the compound used as an inhibitor of PAD4 in the present invention are presented in the following examples. In some embodiments, the provided compound selectively inhibits PAD4 relative to PAD2.

[1281] As used herein, the terms “treatment,” “to treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder or one or more of its symptoms as described herein. In some embodiments, treatment may be administered after one or more symptoms have occurred. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to an individual susceptible to the disease before the onset of symptoms (e.g., in light of a history of symptoms and / or genetic or other susceptibility factors). Treatment may also be continued after symptoms have been resolved, for example, to prevent or delay their recurrence.

[1282] The provided compound is an inhibitor of PAD4 and is therefore useful for treating one or more diseases or disorders associated with PAD4 enzyme activity. Accordingly, in certain embodiments, the present invention provides a method for treating a disease or disorder associated with PAD4 enzyme activity, comprising the step of administering the compound of the present invention or a pharmaceutically acceptable composition thereof to a patient who requires treatment for a disease or disorder associated with PAD4 enzyme activity.

[1283] In one embodiment, the disease or disorder associated with PAD4 enzyme activity is a disease, condition, or disorder mediated by inappropriate PAD4 activity. In some embodiments, the disease or disorder associated with PAD4 enzyme activity is selected from the group consisting of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. In additional embodiments, the disease or disorder associated with PAD4 enzyme activity is rheumatoid arthritis. In additional embodiments, the disease or disorder associated with PAD4 enzyme activity is systemic lupus erythematosus. In additional embodiments, the disease or disorder associated with PAD4 enzyme activity is vasculitis. In additional embodiments, the disease or disorder associated with PAD4 enzyme activity is cutaneous lupus erythematosus. In additional embodiments, the disease or disorder associated with PAD4 enzyme activity is psoriasis.

[1284] In one embodiment, a method for treating rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis is provided, comprising administering a therapeutically effective amount of the provided compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a human subject requiring treatment for rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis.

[1285] In one embodiment, a method for treating rheumatoid arthritis is provided, comprising administering a therapeutically effective amount of a provided compound, its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a human subject requiring treatment for rheumatoid arthritis. In one embodiment, a method for treating systemic lupus is provided, comprising administering a therapeutically effective amount of a provided compound, its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a human subject requiring treatment for systemic lupus. In one embodiment, a method for treating vasculitis is provided, comprising administering a therapeutically effective amount of a provided compound, its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a human subject requiring treatment for vasculitis. In one embodiment, a method for treating cutaneous lupus erythematous isoform is provided, comprising administering a therapeutically effective amount of the provided compound, its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a human subject requiring treatment for cutaneous lupus erythematous isoform. In one embodiment, a method for treating psoriasis is provided, comprising administering a therapeutically effective amount of the provided compound, its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt to a human subject requiring treatment for psoriasis.

[1286] In some embodiments, diseases or disorders associated with PAD4 enzyme activity include acid-induced lung injury, acne (PAPA), acute lymphoblastic leukemia, acute respiratory distress syndrome, Addison's disease, adrenal hyperplasia, adrenal cortical insufficiency, aging, AIDS, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, aspergillosis, allergic conjunctivitis, alopecia, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, weight loss, angina pectoris, angioedema, anophorenal dysplasia-ID, ankylosing spondylitis, anterior segment, inflammation, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune disease, autoimmune hepatitis, bee sting-induced inflammation, Behcet's disease, Behcet's syndrome, Bell's palsy, beryllium poisoning, Blau syndrome, Bone pain, bronchiolitis, burns, bursitis, cancer, cardiac hypertrophy, carpal tunnel syndrome, catabolic disorder, cataract, cerebral aneurysm, chemical irritation-induced inflammation, chorioretinitis, chronic heart failure, chronic lung disease in premature infants, chronic lymphocytic leukemia, chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, connective tissue disease, corneal ulcer, Crohn's disease, cryopyrin-associated periodic syndrome, cryptococcosis, cystic fibrosis, deficiency of interleukin-1 receptor antagonists (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diffuse intrinsic pontine glioma, endometriosis, endotoxemia, epicondylitis, erythroblastopenia, familial amyloid polyneuropathy, familial cold urticaria, familial Mediterranean fever, fetal growth retardation, glaucoma, glomerular disease, glomerulonephritis, gout, gouty arthritis, Graft-versus-host disease, intestinal disease, head injury, headache, hearing loss, heart disease, hemolytic anemia, Henoch-Schönlein purpura, hepatitis, hereditary periodic fever syndrome, herpes zoster and herpes simplex, HIV-1, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D with recurring fever (HIDS), hypoplastic and other anemias, hypoplastic anemia,Idiopathic thrombocytopenic purpura, ataxia pigmentosa, infectious mononucleosis, inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, iritis, irritation-induced inflammation, ischemia / reperfusion, juvenile rheumatoid arthritis, keratitis, kidney disease, parasitic kidney injury, parasitic kidney injury, prevention of kidney transplant rejection, leptospirosis, leukemia, Loeffler syndrome, lung injury, lupus, lupus nephritis, lymphoma, meningitis, mesothelioma, mixed connective tissue disease, Merkle-Wells syndrome (urticarial amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis, myocarditis, mycosarcoma, myelodysplastic syndrome, myositis, rhinosinusitis, necrotizing enterocolitis, neonatal multisystem inflammatory disease (NOMID), Nephrotic syndrome, neuritis, neuropathological disease, non-allergen-induced asthma, obesity, ocular allergy, optic neuritis, tracheal transplant, osteoarthritis, otitis media, Paget's disease, pain, pancreatitis, Parkinson's disease, pemphigus, pericarditis, periodontal fever, periodontitis, peritoneal endometriosis, pertussis, pharyngitis and adenitis (PFAPA syndrome), plant-induced inflammation, pneumonia, pneumonia, Pneumocystis infection, poison ivy / urushiol oil-induced inflammation, polyarteritis nodosum, polychondritis, polycystic kidney disease, polymyositis, psoriasis, psychosocial stress disorder, lung disease, pulmonary hypertension, pulmonary fibrosis, pyoderma gangrene, suppurative sterile arthritis, kidney disease, retinal disease, rheumatic carditis, rheumatic disease, rheumatoid arthritis, sarcoidosis, seborrhea, sepsis, severe pain, sickle cell anemia, Sickle cell anemia, silica-induced disease, Sjögren's syndrome, skin disease, sleep apnea, solid tumor, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid hemorrhage, sunburn, temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue transplantation, TNF receptor-linked periodic syndrome (TRAPS), toxoplasmosis, transplantation, traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticaria,It is selected from the group consisting of uveitis and Wegener's granulomatosis, interstitial lung disease, psoriatic arthritis, juvenile idiopathic arthritis, Sjögren's syndrome, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, antiphospholipid antibody syndrome, sepsis, deep vein thrombosis, fibrosis, Alzheimer's disease, scleroderma, and CREST syndrome.

[1287] In one embodiment, the present invention provides a compound for therapeutic use or a pharmaceutically acceptable salt thereof. In another embodiment, the present invention provides a compound for therapeutic use or a pharmaceutically acceptable salt thereof for therapeutic use in the treatment of a disease or disorder mediated by inappropriate PAD4 activity. In another embodiment, the present invention provides a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof for therapeutic use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis. In another embodiment, the present invention provides a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof for therapeutic use in the treatment of rheumatoid arthritis. In another embodiment, the present invention provides a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt for use in the treatment of systemic lupus. In another embodiment, the present invention provides a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt for use in the treatment of vasculitis. In another embodiment, the present invention provides a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt for use in the treatment of cutaneous lupus erythematous. In another embodiment, the present invention provides a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt for use in the treatment of psoriasis. In another embodiment, the present invention provides the use of a compound or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts in the manufacture of medicines for use in the treatment of disorders mediated by improper PAD4 activity.In another embodiment, the present invention provides a use of a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt in the manufacture of a medicine for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis. In another embodiment, the present invention provides a use of a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt in the manufacture of a medicine for use in the treatment of rheumatoid arthritis. In another embodiment, the present invention provides a use of a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt in the manufacture of a medicine for use in the treatment of systemic lupus. In another embodiment, the present invention provides the use of a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt in the manufacture of a medicine for use in the treatment of vasculitis. In another embodiment, the present invention provides the use of a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt in the manufacture of a medicine for use in the treatment of cutaneous lupus erythematous. In another embodiment, the present invention provides the use of a compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt in the manufacture of a medicine for use in the treatment of psoriasis. In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of a disease or disorder mediated by inappropriate PAD4 activity, comprising the provided compound or its stereoisomers, enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts.In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis, comprising the provided compound or its stereoisomer, enantiomer, diastereoisomer, tautomer, or pharmaceutically acceptable salt. In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of rheumatoid arthritis, comprising the provided compound or its stereoisomer, enantiomer, diastereoisomer, tautomer, or pharmaceutically acceptable salt. In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of systemic lupus, comprising the provided compound or its stereoisomer, enantiomer, diastereoisomer, tautomer, or pharmaceutically acceptable salt. In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of vasculitis comprising the provided compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt. In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of cutaneous lupus erythematous, comprising the provided compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt. In a further embodiment, the present invention provides a pharmaceutical composition for the treatment or prevention of psoriasis comprising the provided compound or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt.

[1288] All features of each aspect of the present invention are applied to all other aspects by making necessary modifications.

[1289] To enable a more complete understanding of the invention as described herein, the following examples are provided. These examples are for illustrative purposes only and should not be interpreted as limiting the invention in any way.

[1290] 5. Examples

[1291] The following examples were prepared, isolated, and characterized using the methods disclosed herein. The following examples demonstrate a partial scope of the invention and are not intended to limit the scope of the invention.

[1292] Details of the various HPLC / LC-MS methods used for the analysis of compounds and intermediates are provided below.

[1293] Method A: Sunfire C18 (4.6 x 150) mm, 3.5 μm column; flow rate 1 ml / min; gradient time 15 min; 10–100% solvent B; monitoring at 254 nm and 220 nm (solvent A: 5% acetonitrile (ACN), 95% water, 0.05% trifluoroacetic acid (TFA); solvent B: 95% ACN, 5% water, 0.05% TFA).

[1294] Method B: Ex-bridged phenyl (4.6 x 150) mm, 3.5 μm column; flow rate 1 ml / min; gradient time 15 min; 10–100% solvent B; monitored at 254 nm and 220 nm (solvent A: 5% ACN, 95% water, 0.05% TFA; solvent B: 95% ACN, 5% water, 0.05% TFA).

[1295] Method C: Kinetex EVO C18 (4.6x100) mm, 2.6 μm, buffer: 0.05% TFA in water, mobile phase C: buffer: ACN (95:5), mobile phase D: ACN: buffer (95:5).

[1296] Method D: Kinetex biphenyl (4.6 x 100) mm, 2.6 μm, buffer: 0.05% TFA in water, mobile phase C: buffer: ACN (95:5), mobile phase D: ACN: buffer (95:5).

[1297] Method E: ExBridge BEH XP C18 (50x2.1) mm, 2.5 μm, time (min): 0-3% B: 0-100 Buffer A: 95% water: 5% ACN; 10 mM ammonium acetate (NH4OAc) B: 5% water: 95% ACN; 10 mM NH4OAc, flow rate: 1.1 ml / min, temperature: 50℃.

[1298] Method F: X-bridge BEH XP C18 (50x2.1) mm, 2.5 μm, time (min): 0-3%, B: 0-100, A: 95% water: 5% ACN; 0.1% TFA, B: 5% water: 95% ACN; 0.1% TFA, flow rate: 1.1 ml / min, temperature: 50℃.

[1299] Method G: ACQUITY UPLC® BEH C18 (3x50) mm, 1.7 μm, buffer: 10 mM NH4OAc, mobile phase A: buffer: ACN (95:5), mobile phase B: buffer: ACN (5:95), flow rate: 0.7 ml / min, method: 0 min-20% B, 20% to 100% B 2 min, 2 to 2.3 min-100%.

[1300] Method H: Kinetex XB C18 (75x3) mm, 2.6 μm, mobile phase A: 10 mM NH4OAc in water, water:ACN (98:02), mobile phase B: 10 mM NH4OAc in water:ACN (02:98), gradient: 20-100%B over 4 minutes, flow rate: 1.0 ml / min.

[1301] Method I: Aquiti UPLC® BEH C18 (3x50) mm, 1.7 μm, buffer: 0.05% TFA in water, mobile phase A: buffer: ACN (95:5), mobile phase B: ACN: buffer (95:5).

[1302] Method J: Column: Halo C18, 3x30 mm, 2.7 μm; Mobile phase A: Water + 0.05% TFA, Mobile phase B: Acetonitrile + 0.05% TFA; Flow rate: 1.5 mL / min; Gradient: 5% B to 95% B at 2.5 min, maintained at 95% for 1 min, 95% B to 5% B at 0.05 min; Detection: MS and UV (254 nm).

[1303] Method K: Column: Sim-Pack XR-ODS, 3x50 mm, 2.2 μm; Mobile phase A: Water / 0.05% TFA, Mobile phase B: Acetonitrile / 0.05% TFA; Flow rate: 1.2000 mL / min; Gradient: 5% B to 95% B at 3.3 min, hold at 95% for 0.7 min, 95% B to 5% B at 0.1 min; Detection: MS and UV (254 nm).

[1304] The general procedure for purification using reverse phase HPLC (RP-HPLC) is as follows. Typically, the sample to be purified is dissolved in DCM:MeOH (2:1), 20 wt% poly(4-vinylpyridine) (Aldrich # 226963) is added to this solution, and the container containing the solution is placed on a shaker for 2 hours. Afterward, the contents are filtered into a clean vial through a 25 mm syringe filter fitted with a 0.45 μm nylon membrane (VWR # 28145-489) and dried using centrifugal evaporation to obtain the purified sample.

[1305] General synthesis procedure:

[1306] Intermediate 1

[1307] 1-amino-3-methoxy-5-(methoxycarbonyl)pyridine-1-um 2,4-dinitrophenolate

[1308]

[1309] O-(2,4-dinitrophenyl)hydroxylamine (10.01 g, 50.3 mmol) was added to a stirred solution of methyl 5-methoxynicotinate (7 g, 41.9 mmol) in tetrahydrofuran (THF, 50 ml) and water (50 ml). The reaction mixture was heated to 40°C, stirred for 12 hours, and filtered to obtain 1-amino-3-methoxy-5-(methoxycarbonyl)pyridine-1-um (10 g, 130%) as a yellowish-brown solid, which was used in subsequent steps without further purification. Liquid chromatography-mass spectrometry (LC-MS) m / z: 183.1 [M+H] + .

[1310] Intermediate 2

[1311] tert-butyl-3-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)propiolate

[1312]

[1313] Tert-butyl propiolate (0.605 g, 4.80 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.153 g, 0.218 mmol) were added to a stirred solution of 1-(cyclopropylmethyl)-2-iodo-1H-pyrrolo[2,3-b]pyridine (1.3 g, 4.36 mmol) in a mixture of triethylamine (TEA, 5 ml) and THF (5 ml). The reaction mixture was heated to 65°C, stirred for 1 hour, and filtered through a Celite layer. The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified using a silica gel column (40 g, Redisep® SiO2 column, eluted with 20% ethyl acetate (EtOAc) in hexane) to obtain the title compound (1.2 g, 93%) as a brown liquid. LC-MS m / z: 297.1 [M+H] + . 1H NMR (300 MHz, chloroform-d) δ ppm: 8.55-8.38 (m, 1H), 7.99-7.87 (m, 1H), 7.26-6.99 (m, 1H), 7.04-6.99 (m, 1H), 4.43-4.06 (m, 2H), 3.26-3.16 (m, 1H), 1.65-1.38 (m, 10H), 1.34-1.07 (m, 1H), 0.59-0.39 (m, 4H).

[1314] Intermediate 3

[1315] 6-chloro-1-(cyclopropylmethyl)-2-iodo-1H-pyrrolo[2,3-b]pyridine

[1316]

[1317] Sodium hydride (2.87 g, 71.8 mmol) was added at 0°C to a stirred solution of 6-chloro-2-iodo-1H-pyrrolo[2,3-b]pyridine (10 g, 35.9 mmol) in dimethylformamide (DMF, 200 ml), the reaction mixture was stirred for 0.5 hours, and then (bromomethyl)cyclopropane (4.50 ml, 46.7 mmol) was added. The reaction mixture was stirred for 1 hour, poured into ice water (200 ml), and extracted with ethyl acetate (3 x 200 ml). The combined organic fractions were washed with water (2 x 300 ml) and brine (2 x 200 ml), dried over sodium sulfate (Na2SO4), filtered, and concentrated to obtain the crude product, which was purified using a silica gel column (80 g, Redycep® silica column, 0-50% EtOAc in hexane as eluent) to obtain the title compound (8 g, 67%) as a yellow solid. LC-MS m / z: 332.9 [M+H] + . 1¹H NMR (400 MHz, chloroform-d) δ ppm: 7.75 (d, J=8.1 Hz, 1H), 7.04 (d, J=8.3 Hz, 1H), 6.79 (s, 1H), 1.46-1.26 (m, 1H), 0.61-0.44 (m, 4H).

[1318] Intermediate 4

[1319] tert-butyl-3-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)propiolate

[1320]

[1321] Tert-butyl propiolate (1.669 g, 13.23 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.422 g, 0.601 mmol) were added to a stirred solution of 6-chloro-1-(cyclopropyl-methyl)-2-iodo-1H-pyrrolo[2,3-b]pyridine (intermediate 3, 4 g, 12.03 mmol) in a mixture of TEA (10 ml) and THF (10 ml). The reaction mixture was stirred at 50°C for 1 hour and filtered through a Celite layer. The filtrate was concentrated under reduced pressure to obtain the crude compound, which was purified using a silica gel column (40 g, Redysep® SiO2 column, eluted with 20% EtOAc in hexane) to obtain the title compound (2.5 g, 63%) as a yellow liquid. LC-MS m / z: 331.1 [M+H] + .

[1322] Intermediate 5

[1323] 6-Bromo-1-(cyclopropylmethyl)-2-ethynyl-1H-indole

[1324]

[1325] Potassium carbonate (K2CO3, 11.18 g, 81 mmol) was added to a stirred solution of dimethyl (1-diazo-2-oxopropyl)phosphonate (51.8 g, 27.0 mmol, 10% solution in acetonitrile) in methanol (MeOH, 50 ml), followed by the addition of 6-bromo-1-(cyclopropylmethyl)-1H-indole-2-carbaldehyde (7.5 g, 27.0 mmol) at 0°C. The reaction mixture was heated to room temperature and stirred for 6 hours, then concentrated under vacuum to obtain the crude residue, which was diluted with water and extracted with EtOAc (2 x 100 ml). The combined organic layer was dried over Na2SO4, filtered, and the filtrate concentrated under reduced pressure to obtain the crude product, which was purified using a silica gel column (40 g, Redycep® SiO2 column, eluted with 0-5% EtOAc in hexane) to obtain the title compound (6.3 g, 85%) as a brown liquid. LC-MS m / z: 276.1 [M+2H] + .

[1326] Intermediate 6

[1327] tert-butyl-3-(6-bromo-1-(cyclopropylmethyl)-1H-indole-2-yl)propiolate

[1328]

[1329] Lithium diisopropylamide (LDA, 17.23 ml, 34.5 mmol) was added at 0°C to a stirred solution of 6-bromo-1-(cyclopropylmethyl)-2-ethynyl-1H-indole (intermediate 5, 6.3 g, 22.98 mmol) in THF (10 ml), the reaction mixture was stirred for 30 minutes, and then Boc2O (5.34 ml, 22.98 mmol) was slowly added. The reaction mixture was stirred for 1 hour, quenched with water, and extracted with EtOAc (2 x 100 ml). The combined organic layer was washed with water (2 x 300 ml) and brine (2 x 200 ml), dried over Na2SO4, filtered, and the filtrate concentrated under reduced pressure. The obtained crude product was purified using a silica gel column (80 g, Redycep® silica column, 0-5% EtOAc in hexane as eluent) to obtain the title compound (6.2 g, 72%). LC-MS m / z: 318.0 [M-isobutene+H] + . 1 ¹H NMR (400 MHz, DMSO-d 6 ) δ ppm: 7.94 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.26 (dd, J=1.5, 8.5 Hz, 1H), 7.21 (s, 1H), 4.17 (d, J=7.0 Hz, 2H), 1.51 (s, 9H), 1.27-1.18 (m, 1H), 0.52-0.40 (m, 4H).

[1330] Intermediate 7

[1331] 1-(cyclopropylmethyl)-2-(trimethylstannyl)-1H-pyrrolo[2,3-b]pyridine

[1332]

[1333] Hexamethyldiantin (0.278 ml, 1.342 mmol) was added to a stirred solution of 1-(cyclopropyl-methyl)-2-iodo-1H-pyrrolo[2,3-b]pyridine (0.2 g, 0.671 mmol) in 1,4-dioxane (1.5 ml), the reaction mixture was degassed with argon for 5 minutes, and then [1,1'-bis(di-tert-butylphosphino)-ferrocene]-dichloropalladium(II) (0.031 g, 0.047 mmol) was added. The reaction mixture was stirred at 70°C for 2 hours, filtered through a Celite layer, and the filtrate was concentrated to obtain a crude product (250 mg), which was used in subsequent steps without further purification. LC-MS m / z: 337 [M+H] + .

[1334] Intermediate 8

[1335] 1-amino-3-(ethoxycarbonyl)pyridine-1-um 2,4-dinitrophenolate

[1336]

[1337] Intermediate 8 was prepared according to a procedure similar to that of Intermediate 1 (10 g, 28.5 mmol, 100%). LC-MS m / z: 168 [M+H] + .

[1338] Intermediate 9

[1339] 1-amino-3-fluoro-5-(methoxycarbonyl)pyridine-1-um 2,4,6-trimethylbenzenesulfonate

[1340]

[1341] O-(methylsulfonyl)hydroxylamine (8.33 g, 38.7 mmol) was added at 0°C to a stirred solution of methyl 5-fluoronicotinate (5 g, 32.2 mmol) in dichloromethane (DCM, 20 ml). The reaction mixture was stirred for 2 hours and concentrated to obtain 1-amino-3-fluoro-5-(methoxycarbonyl)pyridine-1-um (5 g, 91%) as a brown solid, which was used in subsequent steps without further purification. LC-MS m / z: 171.0 [M+H] + .

[1342] Intermediate 10

[1343] 1-(cyclopropylmethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

[1344]

[1345] sec-butyllithium (16.68 ml, 23.36 mmol) was added dropwise to a stirred solution of 1-(cyclopropylmethyl)-1H-indole (2 g, 11.68 mmol) in THF (20 ml) under an argon atmosphere at -78°C. The reaction mixture was stirred for an additional 30 minutes, followed by the addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.173 g, 11.68 mmol). The reaction mixture was stirred at room temperature for 2 hours, quenched with the dropwise addition of water (50 ml), and extracted with EtOAc (2 x 50 ml). The combined organic extract was washed with water (100 ml) and brine (100 ml), dried over Na2SO4, filtered, and the filtrate was evaporated under reduced pressure. The crude product obtained in this way was purified using a silica gel column (EtOAc in hexane), and the purified product was isolated with 15% EtOAc in hexane. The necessary fractions were collected, and the volatile substances were evaporated and dried under reduced pressure to obtain the title compound (2 g, 58%). 1 ¹H NMR (400 MHz, DMSO-d 6) δ ppm: 0.32-0.44 (m, 4 H), 1.16-1.34 (m, 13 H), 4.32 (d, J=6.85 Hz, 2 H), 6.94-7.05 (m, 2 H), 7.16-7.25 (m, 1 H), 7.51-7.60 (m, 2 H).

[1346] Intermediate 11

[1347] 1-(cyclopropylmethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine

[1348]

[1349] Intermediate 11 was prepared according to a procedure similar to that of intermediate 10 (1.3 g, 31%). LC-MS (ESI) m / z: 300.3 [M+H] + .

[1350] Intermediate 12

[1351] 6-Bromo-1-(cyclopropylmethyl)-2-iodo-1H-indole

[1352]

[1353] Sodium hydride (NaH, 1.372 g, 34.3 mmol) was added in a lot at 0°C to a stirred solution of 6-bromo-2-iodo-1H-indole (5.52 g, 17.15 mmol, Ref: Bioorg. Med. Chem. 22(5), 2014, 1708) in DMF (20 ml), the reaction mixture was stirred for 10 minutes, and then (bromomethyl)-cyclopropane (2.498 ml, 25.7 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 16 hours, diluted with cold water (50 ml), and extracted with EtOAc (3 x 50 ml). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure. The crude product obtained in this manner was purified using a silica gel column (24 g, Redycep® SiO2 column, eluted with 10% EtOAc in n-hexane) to obtain the title compound (5 g, 78%). LC-MS m / z: 377 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ ppm: 7.83 (s, 1H), 7.43 (d, J=8.3 Hz, 1H), 7.14 (dd, J=1.8, 8.5 Hz, 1H), 6.82 (s, 1H), 4.13 (d, J=6.8 Hz, 2H), 1.31-1.13 (m, 1H), 0.51-0.41 (m, 4H).

[1354] Intermediate 13

[1355] 1-amino-3-chloro-5-(methoxycarbonyl)pyridine-1-um-2,4,6-trimethylbenzenesulfonate

[1356]

[1357] O-(methylsulfonyl)hydroxylamine (2.6 g, 11.66 mmol) was added at 0°C to a stirred solution of methyl 5-chloronicotinate (2 g, 11.66 mmol) in DCM (40 ml). The reaction mixture was stirred at room temperature for 2 hours and evaporated under reduced pressure to obtain crude 1-amino-3-chloro-5-(methoxycarbonyl)pyridine-1-um (2.1 g, 96%) as a white solid, which was used in subsequent steps without further purification. LC-MS m / z: 187.2 [M+H] + .

[1358] Intermediate 14

[1359] Ethyl 6-bromo-1-(cyclopropylmethyl)-1H-indole-2-carboxylate

[1360]

[1361] Potassium carbonate (10.3 g, 74.6 mmol) was added to a stirred solution of ethyl 6-bromo-1H-indole-2-carboxylate (10 g, 37.3 mmol) in DMF (60 ml), followed by the addition of (bromomethyl)cyclopropane (5.0 g, 37.3 mmol). The reaction mixture was stirred for 16 hours, and potassium carbonate (5 g) and (bromomethyl)cyclopropane (2.5 g) were added. The resulting reaction mixture was heated at 50°C for 2 hours, diluted with water (150 ml), and extracted with ethyl acetate (3 x 150 ml). The combined organic layer was concentrated under vacuum to obtain ethyl 6-bromo-1-(cyclopropylmethyl)-1H-indole-2-carboxylate (10 g, 83%) as a brown solid, which was used without further purification. LC-MS m / z: 322.0 [M+H] + .

[1362] Intermediate 15

[1363] (6-bromo-1-(cyclopropylmethyl)-1H-indole-2-yl)methanol

[1364]

[1365] LiBH4 (15.52 ml, 62.1 mmol, 4 M in THF) was added at 0°C to a stirred solution of intermediate 14 (10 g, 31 mmol) in THF (50 ml). The reaction mixture was heated to room temperature over 1 hour, stirred for 16 hours, cooled to 0°C, and an additional amount of LiBH4 (15.52 ml, 62.1 mmol, 4 M in THF) was added dropwise. The reaction mixture was stirred at room temperature for 6 hours, cooled to 0°C, quenched by slowly adding a saturated ammonium chloride solution (addition needed carefully, sudden generation of gas is observed), stirred for ~45 minutes, and extracted with ethyl acetate (4 x 100 ml). The organic layer was separated, dried over Na2SO4, filtered, and concentrated to obtain the crude product, which was further purified using a silica gel column (0-30% ethyl acetate / petroleum ether) to obtain 6-bromo-1-(cyclopropylmethyl)-1H-indole-2-yl)methanol (8.5 g, 98%). LC-MS m / z: 280.1 [M+H] + .

[1366] Intermediate 16

[1367] 6-Bromo-1-(cyclopropylmethyl)-1H-indole-2-carbaldehyde

[1368]

[1369] Manganese dioxide (10.3 g, 119 mmol) was added to a stirred solution of intermediate 15 (8.3 g, 29.6 mmol) in THF (50 ml). The reaction mixture was stirred at 45°C for 2 hours and filtered through a Celite layer. The filtrate was concentrated under vacuum to obtain 6-bromo-1-(cyclopropylmethyl)-1H-indole-2-carbaldehyde (7.6 g, 92%) as a brown syrup, which was used without further purification. LC-MS m / z: 278.1 [M+H] + .

[1370] Intermediate 17

[1371] (E)-6-bromo-1-(cyclopropylmethyl)-2-(2-nitroprop-1-en-1-yl)-1H-indole

[1372]

[1373] Ammonium acetate (122 mg, 1.582 mmol) was added to a stirred solution of intermediate 16 (400 mg, 1.438 mmol) in nitroethane (2 ml, 28.0 mmol). The reaction mixture was stirred at 90°C for 2 hours, diluted with water (5 ml), and extracted with ethyl acetate (2 x 10 ml). The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to obtain (E)-6-bromo-1-(cyclopropylmethyl)-2-(2-nitroprop-1-en-1-yl)-1H-indole as a yellow liquid (420 mg), which was used in subsequent steps without purification. LC-MS retention time: 1.26 min, m / z = 335.1 [M+H] +

[1374] Intermediate 18

[1375] Ethyl 2-(6-bromo-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-carboxylate

[1376]

[1377] Intermediate 8 (75 mg, 0.447 mmol) and copper(I) iodide (6 mg, 0.03 mmol) were added to a stirred solution of intermediate 17 (50 mg, 0.149 mmol) in DMF (1 ml). The reaction mixture was stirred at 80°C for 30 hours, concentrated to remove DMF, water (10 ml) was added, and the contents were extracted with ethyl acetate (3 x 50 ml). The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to obtain the crude product, which was purified using a silica gel column (0-5% methanol in dichloromethane) to obtain ethyl 2-(6-bromo-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-carboxylate (20 mg, 30%). LC-MS (ES): m / z = 452.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.19 (s, 1H), 7.90 (s, 1H), 7.83 (d, J=9.5 Hz, 1H), 7.62-7.58 (m, 2H), 7.24-7.20 (m, 1H), 6.91 (s, 1H), 4.50 (d, J=7.0 Hz, 2H), 4.36 (q, J=7.0 Hz, 2H), 2.42 (s, 3H), 1.36 (t, J=7.0 Hz, 3H), 1.11 (m, 1H), 0.32-0.26 (m, 2H), 0.18-0.13 (m, 2H).

[1378] Intermediate 19

[1379] Ethyl 2-(6-bromo-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-carboxylate

[1380]

[1381] Intermediate 19 was prepared using appropriate reactants following a procedure similar to that of intermediate 18. LC-MS retention time: 1.76 min, m / z: 468.2 [M+H] (Method G). 1 H NMR (400 MHz, chloroform-d) δ ppm: 8.91 (s, 1H), 8.50 (s, 1H), 7.80 (dd, J=3.01, 1.51 Hz, 1H), 7.43-7.60 (m, 1H), 6.85-6.91 (m, 1H), 6.75 (s, 1H), 4.37 (d, J = 6.5 Hz, 2H), 4.02 (s, 3H), 3.93 (s, 3H), 2.56-2.62 (m, 3H), 1.15-1.34 (m, 1H), 0.33-0.46 (m, 2H), 0.13-0.18 (m, 2H).

[1382] Intermediate 20

[1383] 6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine

[1384]

[1385] Sodium hydride (60% w / w, 1.31 g, 32.8 mmol) in mineral oil was added little by little at 0°C to a stirred solution of 6-chloro-1H-pyrrolo[2,3-b]pyridine (5 g, 32.8 mmol) in DMF (25 ml), and the reaction mixture was stirred for 15 minutes, followed by the slow addition of (bromomethyl)cyclopropane (4.42 g, 32.8 mmol) over 5 minutes. The reaction mixture was heated to room temperature and stirred for 16 hours, quenched with water (50 ml), and extracted with ethyl acetate (3 x 50 ml). The combined organic layer was concentrated under vacuum to obtain the crude product, which was purified using a silica gel column (0-5% ethyl acetate / petroleum ether) to obtain 6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine (6.5 g, 96%). LC-MS retention time: 1.85 min, m / z: 207.0 [M+H] (Method G).

[1386] Intermediate 21

[1387] 6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-carbaldehyde

[1388]

[1389] sec-butyllithium (10.37 ml, 14.52 mmol, 1.4 M in cyclohexane) was added at -78°C to a stirred solution of intermediate 20 (2 g, 9.68 mmol) in THF (20 ml), the contents were stirred for 30 minutes, and then DMF (2 ml, 25.8 mmol) was added. The reaction mixture was heated to -20°C and then to room temperature, stirred for 12 hours, cooled to -10°C, and quenched by adding a saturated ammonium chloride solution. The reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organic layer was dried over sodium sulfate, filtered, and the filtrate concentrated under vacuum to obtain the crude product, which was purified using a silica gel column (0 to 15% ethyl acetate / petroleum ether) to obtain 6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-carbaldehyde (1.45 g, 64%) as a grayish-white crystalline solid. LC-MS retention time: 1.85 min, m / z: 235.0 [M+H] (Method G).

[1390] Intermediate 22

[1391] (E)-6-chloro-1-(cyclopropylmethyl)-2-(2-nitroprop-1-en-1-yl)-1H-pyrrolo[2,3-b]pyridine

[1392]

[1393] Intermediate 22 was prepared using Intermediate 21 following a procedure similar to that of Intermediate 17. LC-MS retention time: 1.17 min, m / z: 292.2 [M+H] (Method G).

[1394] Intermediate 23

[1395] Ethyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-carboxylate

[1396]

[1397] Intermediate 23 was prepared using Intermediate 22 and Intermediate 8 according to a procedure similar to that of Intermediate 18. LC-MS retention time: 1.66 min, m / z: 409.1 [M+H] (Method G).

[1398] Intermediate 24

[1399] methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-chloro-3-methylpyrazolo[1,5-a]pyridin-6-carboxylate

[1400]

[1401] Intermediate 24 was prepared as a viscous liquid using Intermediates 13 and 22 according to a procedure similar to that of Intermediate 18. LC-MS (ES): m / z : 429.1 [M+H] + .

[1402] Intermediate 25

[1403] Ethyl 7-(1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole-2-carboxylate

[1404]

[1405] K2CO3 (15.46 g, 112 mmol) and PdCl2 (dppf).CH2Cl2 (3.05 g, 3.73 mmol) were added to a stirred solution of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (11.53 g, 37.3 mmol) and ethyl 7-bromo-1H-indole-2-carboxylate (10 g, 37.3 mmol) in dioxane (200 ml). The reaction mixture was purged with nitrogen for 2 minutes, stirred at 100°C for 3 hours, filtered through a Celite layer, and the Celite layer was thoroughly washed with ethyl acetate. The combined filtrate was concentrated under reduced pressure to obtain the crude product, which was purified using a silica gel column (0-30% ethyl acetate in petroleum ether) to obtain the title compound (11.3 g, 82%) as a viscous liquid. LC-MS m / z: 369.4 [MH] + . 1H NMR (300 MHz, DMSO-d 6 ) δ ppm: 11.43 (s, 1H), 7.57 (d, J=7.2 Hz, 1H), 7.21 (d, J=4.0 Hz, 1H), 7.24-7.04 (m, 2H), 5.96 (br, s, 1H), 4.34 (q, J=7.1 Hz, 2H), 4.08-3.99 (m, 2H), 3.62 (t, J=5.7 Hz, 2H), 1.51-1.45 (m, 2H), 1.46 (s, 9H), 1.34 (t, J=7.2 Hz, 3H).

[1406] Intermediate 26

[1407] Ethyl 7-(1-(tert-butoxycarbonyl)piperidine-4-yl)-1H-indole-2-carboxylate

[1408]

[1409] Pd / C (7.18 g, 6.75 mmol, 50% wet) was added to a stirred solution of intermediate 25 (5.0 g, 13.50 mmol) in nitrogen-purged methanol (100 ml), and the reaction mixture was stirred for 4 hours under an H2 atmosphere. The reaction mixture was filtered through a Celite layer, and the filtrate was concentrated under reduced pressure to obtain ethyl 7-(1-(tert-butoxycarbonyl)piperidine-4-yl)-1H-indole-2-carboxylate (4.95 g, 98%). LC-MS m / z: 371.4 [MH] + . 1 ¹H NMR (300 MHz, DMSO-d 6 ) δ ppm: 11.84 (s, 1H), 7.49 (d, J=7.6 Hz, 1H), 7.21-7.01 (m, 3H), 4.36 (q, J=7.1 Hz, 2H), 4.16-4.04 (m, 4H), 3.61-3.42 (m, 1H), 1.90-1.74 (m, 2H), 1.59-1.47 (m, 2H), 1.43 (s, 9H), 1.35 (t, J=7.2 Hz, 3H).

[1410] Intermediate 27

[1411] Ethyl 7-(1-(tert-butoxycarbonyl)piperidine-4-yl)-1-(cyclopropylmethyl)-1H-indole-2-carboxylate

[1412]

[1413] K2CO3 (14.47 g, 105 mmol) and (bromomethyl)cyclopropane (14.14 g, 105 mmol) were added to a stirred solution of intermediate 26 (13 g, 34.9 mmol) in DMF (100 ml). The reaction mixture was stirred at 50°C for 12 hours, cooled to room temperature, diluted with water, and extracted with ethyl acetate (3 x 150 ml). The combined organic layer was washed with water and brine solutions, dried over anhydrous sodium sulfate, and volatile substances were evaporated under reduced pressure to obtain a crude product, which was purified using a silica gel column (0-20% ethyl acetate in petroleum ether) to obtain ethyl 7-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-(cyclopropylmethyl)-1H-indole-2-carboxylate (4.8 g, 32%) as a viscous liquid. LC-MS m / z: 427.5 [M+H] + .

[1414] Intermediate 28

[1415] tert-butyl 4-(1-(cyclopropylmethyl)-2-(hydroxymethyl)-1H-indole-7-yl)piperidine-1-carboxylate

[1416]

[1417] LiBH4 in tetrahydrofuran (10.08 ml, 40.3 mmol) was added to a stirred solution of intermediate 27 (4.3 g, 10.08 mmol) in tetrahydrofuran (80 ml) at 0°C. The reaction mixture was heated to room temperature, stirred for 48 hours, quenched with a saturated ammonium chloride solution, and extracted with ethyl acetate (4 x 50 ml). The combined organic layer was washed with water and brine solutions, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to obtain a crude product, which was purified using a silica gel column (0-70% ethyl acetate in petroleum ether) to obtain tert-butyl 4-(1-(cyclopropylmethyl)-2-(hydroxymethyl)-1H-indole-7-yl)piperidine-1-carboxylate (3.7 g, 95%) as a viscous liquid. LC-MS m / z: 385.4 [M+H] + . 1 ¹H NMR (300 MHz, DMSO-d 6 ) δ ppm: 7.33 (d, J=6.8 Hz, 1H), 7.03-6.90 (m, 2H), 6.38 (s, 1H), 5.24 (br, t, 1H), 4.60 (s, 2H), 4.30 (d, J=5.3 Hz, 2H), 4.22-3.98 (m, 2H), 3.59-3.38 (m, 1H), 3.02-2.74 (m, 2H), 1.88-1.80 (m, 2H), 1.74-1.50 (m, 2H), 1.43 (s, 9 H), 1.19-1.01 (m, 1H), 0.55-0.37 (m, 2H), 0.36-0.19 (m, 2H).

[1418] Intermediate 29

[1419] tert-butyl 4-(1-(cyclopropylmethyl)-2-formyl-1H-indole-7-yl)piperidine-1-carboxylate

[1420]

[1421] Manganese dioxide (9.04 g, 104 mmol) was added to a stirred solution of intermediate 28 (4 g, 10.40 mmol) in tetrahydrofuran (60 ml). The reaction mixture was heated to 40°C, stirred for 2 hours, filtered through a Celite layer, and washed with ethyl acetate. The combined filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(1-(cyclopropylmethyl)-2-formyl-1H-indole-7-yl)piperidine-1-carboxylate (3.8 g, 96%). LC-MS m / z: 383.4 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ ppm: 9.84 (s, 1H), 7.63 (dd, J=1.3, 7.8 Hz, 1H), 7.42-7.33 (m, 1H), 7.30 (s, 1H), 7.32 (s, 1H), 7.18 (t, J=7.6 Hz, 1H), 5.32 (s, 1H), 4.83 (d, J=6.0 Hz, 2H), 4.47-4.23 (m, 2H), 3.81-3.72 (m, 1H), 3.64-3.48 (m, 1H), 2.93 (br, t, J=12.3) Hz, 2H), 2.01-1.95...

Claims

Claim 1 A compound of chemical formula (Ia) or a salt thereof that is permitted by the law. Here Is Selected from; Is Selected from; X1 is independently selected from CR2 and N; X2 is independently selected from CR4 and N; X3 is independently selected from O and S; X4 is independently selected from CR2 and N; provided that X1 and X4 are not both N; X5 is independently selected from O and S; X6 is independently selected from CR4 and N; provided that 1) X2 and X6 are not both N; 2) where X2 and X6 are both CR4, one of R4 is H; and R1 is an -NH-C independently substituted with one or more substituents selected from F, Cl, and NH2. 1-5 Selected from alkyl, 4-10-membered heterocyclyl, and -NH-4-10-membered heterocyclyl, wherein the heterocyclyl is F, Cl, CN, C 1-3 Alkyl, =N-OR b , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=NH)C 1-3 Alkyl, -NR a C(=O)OR b Optionally substituted with one or more substituents selected from , carbocyclil, and heterocyclil; R2 is independently optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH C 1-4 Alkyl, and -OC 1-4 Selected from alkyls; R3 is independently H, F, Cl, CN, -C(=O)OR b , and C optionally substituted with one or more substituents selected from F, Cl, OH, NH2, and N3 1-3 Selected from alkyls; R4 is independently H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkinyl, -(CR d R d ) r OR b , -(CR d R d ) r S(O) p R c , -(CR d R d ) r S(O) p NR a R a , -(CR d R d ) r NR a S(O) p R c , -(CR d R d ) r NR a R a , -(CR d R d ) r NR a C(=O)R b , -(CR d R d ) r NR a C(=O)OR b , -(CR d R d ) r NR a C(=O)NR a R a , -(CR d R d ) r C(=O)R b , -(CR d R d ) r C(=O)OR b , -(CR d R d ) r C(=O)NR a R a , -(CR d R d ) r OC(=O)R b , -(CR d R d ) r OC(=O)OR b , -(CR d R d ) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyl; R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f is independently F, Cl, Br, CN, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 2 In claim 1, a compound having the chemical formula (IIa)-(XIII) or a salt thereof that is permitted by the law. Claim 3 In paragraph 2, a compound having the chemical formula (IIa) or a salt thereof that is permitted by the regulations. Here, R1 is independently Selected from; R2 is independently optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH, C 1-3 Alkyl, and OC 1-3 Selected from alkyl; R3 is independently optionally substituted with one or more substituents selected from H, F, Cl, and F, Cl, and OH. 1-3 Selected from alkyls; R4 is independently H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, =O, 1 or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, C(=O)R b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f is independently F, Cl, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 4 In claim 1, a compound having the chemical formula (IIIa) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH, C 1-3 Alkyl, and OC 1-3 Selected from alkyl; R3 is independently optionally substituted with one or more substituents selected from H, F, Cl, and F, Cl, and OH. 1-3 Selected from alkyls; R4 is independently H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, =O, 1 or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyls; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f is independently F, Cl, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 5 In paragraph 3 or 4, R1 independently Selected from; R2 is independently selected from H, F, Cl, CH3, and OCH3; R3 is independently selected from H, F, Cl, CH3, and CH2OH; R4 is independently selected from H, F, Cl; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-5 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r Selected from -4-10-membered heterocyclils; R5 is independently H, F, Cl, =O, 1 or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O)2R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O)2R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 independently H and one or more R e C arbitrarily substituted as 1-65 Selected from alkyl; R7 is H; and R8 is one C 3-6 C substituted with a cycloalkyl group 1-3 It is alkyl and;R a H and C independently 1-4 Selected from alkyl; R b H, C independently 1-4 Selected from alkyl; R c Ga C 1-4 A compound or a salt thereof that is alkyl and r is independently selected from 0, 1, and 2 in each case. Claim 6 In paragraph 5, C in which R4 is independently optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH. 1-5 Alkyl, C 3-6 cycloalkyl, Selected from; R5 independently H, F, Cl, =O, 1 or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 independently H and C 1-5 A compound selected from alkyls or a salt thereof that is pharmaceutically permissible. Claim 7 In Paragraph 6, R4 independently A compound selected from or a pharmaceutically permissible salt thereof. Claim 8 In claim 1, a compound having the chemical formula (IVa) or a salt thereof that is pharmaceutically permissible. Here, R1 is independently Selected from; R2 is independently optionally substituted with one or more substituents selected from H, F, Cl; F, Cl, and OH, C 1-3 Alkyl, and OC 1-3 Selected from alkyl; R3 is independently optionally substituted with one or more substituents selected from H, F, Cl, and F, Cl, and OH. 1-3 Selected from alkyls; R4 is independently H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, =O, 1 or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f is independently F, Cl, OH, OC 1-5 C optionally substituted with alkyl, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 9 In paragraph 8, R1 independently Selected from; R2 is independently selected from H, F, Cl, and OCH3; R3 is independently selected from F, Cl, and CH3; R4 is independently selected from H, Selected from; R5 independently H, =O, C 1-4 Selected from alkyl, OH, and NH2; R6 is independently H, one or more R e C arbitrarily substituted as 1-5 Alkyl, and -C(=O)R b Selected from; R7 is H; and R8 is arbitrarily substituted with cyclopropyl C 1-2 It is alkyl and;R b A independently has H, one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R e independently NH2, and one or more R f C arbitrarily substituted as 1-5 Selected from alkyl; R f ga independently F, Cl, OH, and OC 1-5 A compound selected from alkyls or a salt thereof that is pharmaceutically permissible. Claim 10 In Paragraph 9, R4 independently A compound selected from or a pharmaceutically permissible salt thereof. Claim 11 In claim 1, a compound having the chemical formula (Va) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently selected from H, F, Cl, CH3, and OCH3; R3 is independently selected from H, F, Cl, CN, CH3, and CH2OH; R4 is independently selected from H, F, Cl, and -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, =O, 1 or more R e C arbitrarily substituted as 1-4 Alkyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, one or more R f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 12 In Paragraph 11, R1 independently Selected from; R2 is CH3; R3 is CH3; and R4 is independently Selected from; R7 is H; and R8 is arbitrarily substituted with cyclopropyl C 1-2 Alkyl phosphide compound or a pharmaceutically permissible salt thereof. Claim 13 In claim 1, a compound having the chemical formula (VIa) or a salt thereof that is pharmaceutically permissible. Here, R1 is independently Selected from; R3 is independently selected from H, F, and CH3; R4 is independently selected from H, F, Cl, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 14 In Paragraph 13, R1 independently Selected from; R3 is CH3; R4 is independently F, Cl, Selected from; R7 is H; and R8 is arbitrarily substituted with cyclopropyl C 1-2 Alkyl phosphide compound or a pharmaceutically permissible salt thereof. Claim 15 In claim 1, a compound having the chemical formula (VII) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently selected from H, F, Cl, CH3, and OCH3; R3 is independently selected from H, F, and CH3; R4 is independently selected from H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 16 In claim 1, a compound having the chemical formula (VIII) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently selected from H, F, and OCH3; R3 is independently selected from H, F, and CH3; R4 is independently selected from H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyl; R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 17 In claim 1, a compound having the chemical formula (IX) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, and OCH3; R3 is independently selected from H, F, Cl, CH3, CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3; R4 is independently selected from H, F, Cl, Br, and -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 18 In claim 1, a compound having the chemical formula (X) or a salt thereof that is permitted by the constraints. Here, R1 is independently Selected from; R2 is independently selected from H, FCH3, CH2OH, CH2CH2OH, and OCH3; R3 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3; R4 is independently selected from H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 19 In claim 1, a compound having the chemical formula (XI) or a salt thereof that is permitted by the constraints. Here, R1 is independently Selected from; R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, and OCH3; R3 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3; R4 is independently selected from H, F, Cl, Br, and -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyl; R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 20 In claim 1, a compound having the chemical formula (XII) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently selected from H, F, CH3, CH2OH, CH2CH2OH, and OCH3; R3 is independently selected from H, F, and CH3, CH2OH, CH2CH2OH, CH2NH3, CH2CH2NH2, and CH2CH2N3; R4 is independently selected from H, F, Cl, Br, and -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyl; R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 21 In any one of paragraphs 16 through 19, R4 independently H, F, Cl, Br, A compound selected from or a pharmaceutically permissible salt thereof. Claim 22 In claim 1, a compound having the chemical formula (XIII) or a salt thereof that is permitted by the law. Here, R1 is independently Selected from; R2 is independently selected from H, F, CH3, and OCH3; R3 is independently selected from H, F, and CH3; R4 is independently selected from H, F, Cl, Br, -C(=O)R b ; F, Cl, OH, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl; F, Cl, OH, and C 3-6 -NH-C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Alkyl, -(CH2) substituted with one or more R5s r -aryl, -OC substituted with one or more R5s 1-6 Alkyl, -(CH2) substituted with one or more R5s r -C 3-12 -(CH2) comprising a cycloalkyl, and 1 to 5 heteroatoms selected from a carbon atom and N, NR6, O, and S, substituted with one or more R5s r -Selected from 4-10-membered heterocyclils; R5 is independently H, F, Cl, Br, CN, =O, one or more R e C arbitrarily substituted as 1-4 Alkyl, one or more R e C arbitrarily substituted as 2-4 Alkenyl, 1 or more R e C arbitrarily substituted as 2-4 alkynyl, -(CH2) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R6 is independently H, one or more R e C arbitrarily substituted as 1-6 Alkyl, -S(O) p R c , -S(O) p NR a R a , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , one or more R e C arbitrarily substituted as 3-6 Cycloalkyl, one or more R e An aryl arbitrarily substituted with , and one or more R e Selected from heterocyclils arbitrarily substituted with; R7 is independently selected from H, F, and Cl; R8 is independently selected from H, and F, Cl, and C 3-6 C optionally substituted with one or more substituents selected from cycloalkyl 1-6 Selected from alkyl; R a is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r - Selected from heterocyclils; or R a and R a is one or more R together with the nitrogen atom to which both are attached. e Forming a heterocyclic ring arbitrarily substituted with;R b is independently H, 1 or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r Selected from heterocyclil; R c is independently one or more R e C arbitrarily substituted as 1-6 Alkyl, one or more R e C arbitrarily substituted as 2-6 Alkenyl, 1 or more R e C arbitrarily substituted as 2-6 Alkynyl, one or more Rs e -(CH2) arbitrarily substituted as r -C 3-10 Carbocyclil, and one or more R e -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R d is independently H, and one or more R e C arbitrarily substituted as 1-6 Selected from alkyl; R e is independently F, Cl, Br, CN, NH2, -NH-C 1-4 Alkyl, -N(C 1-4 Alkyl)2, =O, OH, -OC 1-6 Alkyl, -CO2H, one or more R f C arbitrarily substituted as 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, one or more Rs f -(CH2) arbitrarily substituted as r -C 3-6 Cycloalkyl, one or more R f -(CH2) arbitrarily substituted as r -aryl, and one or more R f -(CH2) arbitrarily substituted as r -Selected from heterocyclil;R f C independently substituted with F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkinyl, C 3-6 Selected from cycloalkyl, and phenyl; p is independently selected from 0, 1, and 2 in each case; and r is independently selected from 0, 1, 2, 3, and 4 in each case. Claim 23 In claim 1, a compound having the chemical formula (XIV) or a salt thereof that is pharmaceutically permissible. Here, X2 is independently selected from CR4 and N; X3 is independently selected from O and S; and R1 is independently Selected from; R2 is independently selected from CH2OH, CH2CH2OH, and OCH3; R3 is independently selected from CH2OH, CH2CH2OH, CH2NH2, CH2CH2NH2, and CH2CH2N3; R4 is independently -OC substituted with H and one or more R5s 1-4 Selected from alkyls; provided that both R4s are substituted with one or more R5s -OC 1-4 It is not an alkyl group; R5 is independently OH, and one or more R e Selected from heterocyclils arbitrarily substituted with; R8 is independently H, and C 3-6 C optionally substituted with a cycloalkyl 1-6 Selected from alkyl; R e is independently NH2 and C 1-3 Selected from alkyls. Claim 24 In paragraph 23, a compound having the chemical formula (XV) or a salt thereof that is permitted by the law. Here, R4 is independently H, OCH3, OCH2CH2OH, Selected from; R8 is C 3-6 C substituted with a cycloalkyl group 1-3 It is alkyl and;R e is independently NH2 and C 1-2 Selected from alkyls. Claim 25 In claim 1, a compound selected from the following or a pharmaceutically acceptable salt thereof: 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]- Heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;5-(2-(6-((7R)-7-amino-2-a Zabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7 -amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone; 3((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone; 5-(2-(6-((7R)-7-amino NO-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one; 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-indole-2-yl)-4-fluoro-3-methylpyrazolo[1, 5-a]pyridine-6-yl)methanone; 6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)isoindolin-1-one; ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-fluoro-4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6- 1)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-fluoro-3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)-2-fluorobenzamide;( (7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;6-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one; 5-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one; ((7R)-7-amino-2-azabicyclo [2.2.1]Heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2 .1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1,1,1-trifluoro-2-hydroxypropane-2-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2. 2.1]Heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1,1,1-trifluoro-2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(1-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-(4-aminopiperidin-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzo[b]thiophene-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2. 2.1]Heptane-2-yl)(2-(6-(4-aminopiperidin-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-methylbenzofuran-6-yl)methanonecyclopropylmethyl)-1H-indole-6-yl)isoindolin-1-one;5-(2-(6- ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2- 1)(2-(1-(cyclopropylmethyl)-6-methyl-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone; 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylbenzofuran-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-fluorobenzamide; ((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-methoxypyridine-4-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(6-(4-aminopiperidin-1-yl)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-( 2-hydroxypropane-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl)-4-methoxy-3-methylbenzofuran-6-yl)methanone;((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-yl)(2-(1-(cyclopropylmethyl)-6-(2-hydroxypropane-2-yl)-1H-indole-2-yl)-3-methylbenzofuran-6-yl)methanone;N-[5-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-2-yl}-1-(cyclopropylmethyl)-1H-phosphor [dol-6-yl)pyridin-2-yl]acetamide; (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-indole-2-yl]-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidin-3-amine; 3-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol; 5 -(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylpyridin-2-carboxamide;4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)morpholine-3-one;(7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine;(7R)-2-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-indole-2-yl]-4-fluoro-3-methylpyrazolo rho[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine;(7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine;3-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[ 1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol; 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one; 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.

2. 1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide;(7R)-2-{2-[1-(cyclopropylmethyl)-6-(7-fluoro-1H-indazole-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine;methyl N-[5-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate;4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)morpholine-3-one; 1-[4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]pyrrolidin-2-one; (7R)-2-{2-[1-(cyclopro (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-6-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine; (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazole-5-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine; N-[7-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1 ,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)-4-chloro-1-methyl-1H-indazole-3-yl]methanesulfonamide; 1-[2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)phenyl]imidazolidin-2-one; 4-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl} {2-1-(cyclopropylmethyl)-1H-indole-6-yl)-2-chlorobenzamide; (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine; (7R)-2-{2-[1-(cyclopropylmethyl)-6-(morpholine-4-yl)-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridine-6-carbonyl}-2-azabicyclo[2.2.1]heptane-7-amine;(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(pyrrolidin-1-carbonyl)piperidin-1-yl]-1H-indole-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-carbonyl}-5-fluoropiperidin-3-amine;3-[1-(2-{6-[(3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-indole-6-yl)piperidin-4-yl]-1,3-oxazolidin-2-one;2-(2-{6-[(7R)-7-amino- 2-azabicyclo[2.2.1]heptan-2-carbonyl]-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1-difluoropropan-2-ol; 2-(2-{6-[(7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-carbonyl]-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1,1-trifluoropropan-2-ol; ((3R,5R)-3- Amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3 R,5R)-3-amino-5-fluoropiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone; (R)-(3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxycyclobutane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;(R)- (3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3R,5R)-3-amino-5-fluoropiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a ]pyridine-6-yl)methanone;(R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one;(S)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one;1-( 4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((3R,5R)-3-amino-5-fluoropiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[ 1,5-a]pyridine-6-yl)methanone; 1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one; (R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one ;(R)-1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one;(R)-1-(4-(2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1 -one;1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethethane-1-one;1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethane-1-one;1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxyethane-1-one;(R)-1-(4-(2-(6-(3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-hydroxyethane-1-one;1-(4-(2-(6-((3R, 5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-ethoxyethanol-1-one;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;((3R,5R)-3 -amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1R,3S)-3-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone; ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone; 1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one;1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)-2-methoxyethanol-1-one;(R)-(3-aminopiperidin-1-yl)(2-(1-( cyclopropylmethyl)-7-(1-(3-hydroxy-3-(trifluoromethyl)cyclobutane-1-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydro- 2H-pyran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridine-6-yl)methanone;((R)-3-aminopiperidine-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-(tetrahydrofuran-2-carbonyl)piperidine-4-yl)-1H-indole-2-yl)-3-methyl Pyrazolo[1,5-a]pyridine-6-yl)methanone;(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)(3-hydroxycyclobutyl)methanone;methyl 4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-carboxylate;(2R)-1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5 -a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)-2-hydroxypropan-1-one;(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidine-1-yl)(thiophene-2-yl)methanone;1-(4-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one;1-(4-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)piperidin-1-yl)ethane-1-one;1-(4-(2-(6-((3R,5R)-3 -amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-3-methylbutan-1-one;((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(3-hydroxycyclobutan-1-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;(R)-1-(4-(2-(6- ((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-5-fluoro-1H-indole-7-yl)piperidin-1-yl)-2-methoxypropan-1-one;((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-5-fluoro-7-(1-(tetrahydro-2H-pyran-2-carbonyl)piperidin-4-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;1-(4-(2-(6-((3R,5R)-3-ami (no-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)piperidin-1-yl)-2-methoxyethanol-1-one; ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1s,4s)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)methanone;1-(3-(2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)-2-methoxyethane-1-one;((R)-3-aminopiperidin-1-yl)(2-(1-(cyclopropylmethyl)-7-(1-((1r,4r)-4-hydroxycyclohexane-1-carbonyl)azetidine-3-yl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a ]pyridine-6-yl)methanone; 1-(3-(2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)azetidine-1-yl)ethane-1-one; 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one ;(R)-(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)(3-aminopiperidine-1-yl)methanone;(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidine-1-yl )methanone;(2-(7-(2-(4-amino-1H-pyrazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridine-6-yl)((3R,5R)-3-amino-5-fluoropiperidin-1-yl)methanone;4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazole[1,5-a]pyridine-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((3R,5R)-3-amino-5 -fluoropiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;(S)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-fluoro-3-methylpyrazolo [1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidin-1-yl)methanone;(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-indole-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6- 1)((3R,5R)-3-amino-5-fluoropiperidin-1-yl)methanone;(S)-5-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one; 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-indole-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one;(2-(7-(2-(1H-1,2,4-triazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidin-1-yl)methanone;( 2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidin-1-yl)methanone;(R)-(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazole[1,5-a]pyridin-6-yl)(3-aminopiperidin-1-yl)methanone;(R)-(2- (7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidin-1-yl)methanone;(2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5R)-3-amino-5-fluoropiperidin-1-yl)methanone;4 -(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one; 4-(((2-(6-((3R,5R)-3-amino-5-fluoropiperidin-1-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one;(5R)-5-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7 -yl)oxy)methyl)pyrrolidin-2-one;(5R)-5-(((2-(6-((7S)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-4-methoxy-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)- 1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one;(R)-(2-(7-(2-(4H-1,2,4-triazole-4-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidin-1-yl)methanone;(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)((3R,5 R)-3-amino-5-fluoropiperidin-1-yl)methanone; (R)-(2-(7-(2-(1H-imidazole-1-yl)ethoxy)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-3-methylpyrazolo[1,5-a]pyridin-6-yl)(3-aminopiperidin-1-yl)methanone; 4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one;4-(((2-(6-((R)-3-aminopiperidin-1-carbonyl)-3-methylpyrazolo[1,5-a]pyridin-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-c]pyridin-7-yl)oxy)methyl)pyrrolidin-2-one.; Claim 26 A pharmaceutical composition for treating a disease or disorder selected from rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, lupus, Parkinson's disease, and cancer, comprising a compound according to any one of claims 1 to 4, 8 to 20, and 22 to 25, or its stereoisomer, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, and one or more pharmaceutically acceptable carriers. Claim 27 delete Claim 28 delete Claim 29 delete Claim 30 delete Claim 31 delete

Citation Information

Patent Citations

  • Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

    US20190276440A1

  • 2 - (azaindol- 2 -YL) BENZ imidazoles as pad4 inhibitors

    WO2014015905A1

  • Benzoimidazole derivatives as pad4 inhibitors

    WO2016185279A1

  • Aza-benzimidazole inhibitors of pad4

    WO2017100601A1

  • Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity

    WO2017108282A1